var title_f12_9_12432="Straight leg raise exercise";
var content_f12_9_12432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Straight leg raises",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 231px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADnAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1f6cUd+acQDS9P/11xDExzRilxz7Uo6cYpDCjjApcUH8qAG/hRindaXrTAaKMU4dKMZpDsJ6UU7FBFAxoHtTh/kUAUoFAABQBSr1pQOOaBiY4FL096UDmlAHP50AJj0FL/SgD2pcZpgJ06UDpzTsUCgBO5oxS4/GlxSAYf/10Yp2P8mk6dKAG+mKO9OpKAExSY/KnUhHFAxvrSHrTj1pDQA2k7mnHrTT+lACEe1M/CpKYRigBppMU4+tIaBEbc+tNNPI5HpTSOKYxlRn9akIpppAMPpTGHGMVIaaaBEJ6Uhp7D3/SmGmMaab0FOIprdaAGMPb8qaw/LFSHOc9qY3akSRnpUbDP+FSHjpTCD/jQBGaYR71Kw9f1phpjOtppFO780UGYg5pcetHeloGAH40o60nvS0AJSgYpaKQxKWilWgYmOlGOPal9KMfjTAAPWlxQBTqQxoHFO+tJinAe1AAO9GKUAe1L+lMBAO2KXGT0pR0HpS9QetADQPzpQKU0D2zmkAn40tGOKXBzzmgBv4UUtAoAaR7cUmKdj0pCKAGkUmPrTz3xTaAExTT1px460h4oGMNIacetJQA09qQ9OKcaDQBGcZ702nn9Kaf1xTENbjNMI9uKkphA64NAxhphp5FNagBhzTWHtTjSGkIiYEZ96YQKkcZphGOe1MYw96Q8GlIppH5UANPQ4phHWpMD60098UCZEeM54NNPTt61IR14qMjPXrSERn8eDTT+lSkD2qMj26Uxo6yjFAFLSMxMUveilxQMMVh+KPFWj+GIFk1a5YSOMpbwqHlYeuMgAe5Iqz4l1q20DSZr69kEccY+8c9ScAfia+Q/Ffia91fxJPf3DuD5mVU9h2/SnCEqkrR+8pWWrPr3w5rdh4j0eHU9ImMttIShDDDxsOqsuTg9D7gg1pV5F+zXHM/h7X70qVtZ7uKONs8O6qxfAJ7b0H416/j0qqkOSTiAY/OlA7UAYpQKgEIB2pcUYpaBiClxRzS4x6UAGOlABzzzS49aUUAGKXtRzSgUwEx607rQBwKWkITFGKd+FFAxMUYpaKAG4/Ckx2p1GOtADcUhGKdSY6cUAN9KQ06m4/P6UAN/OkI5p2PSkxTGMIpKefxprUAMpMU4j86SgBD7Uw0/FJ+dIQw0xhxweaewGaae3tTAjPFNbrUh/yKY1AyMimkU8000hEbdDwaYR6VK3fPSmMOMZ5HFMCI/Wm/jTzTT7UxjTTWFPNNbHekIjIyaYR6CpW796jb6UCI25OM1GwP1qZsY4qM5OQaYHVUtMU8U7PFIgdilLBQS3AHJ9qQfSs/xBfJpmk3N3LgRwRtM+fRVJx+OMVMnZXGjxf43eIlvdWt9IjYlbdhLIA/y7j0BHfA/ma8M1Z92oTkkE5wceuK1dT1Z7u9u7+8cvcTMWAP8RJ5P0rniSzlick816FGHs4KPUmbuz63/Z8WNfhPp3lSFybu5MgOPkbcOP8AvkKefX6V6L9K8Q/Zd1fztK1zRnk5haO9iT2PySH/ANFV7gBn61zYhNVGWtgxRjj2pcUuKxGNopxooGNxTgMjAo60uMUAAFKO2KXHNKOtAABRilA9qUUxCYpaUDmjFACEUUoHFGOKBiYopcc0YoASkpwpKAENITS/SkpANIpMfnTsf5NNI9aAEPOaaRTu/HWhhn60wGEY7CmnOM0+m4oGNIPrTSKcQM9M00570AIabjP/ANanUlADT3ph98085NNPrQIjI9eaYakI5phpjGEdaaRzTzTTSBjDnmo3HGalNMb7poEQk8U2nGmnFMYlNYU6kboaAGHk4ph46/jUhphoJI2/zimsD+XWpCuck5pp70AdCDTweBUAbinlqGiCwpzXEfF+Vh4I1qJCmTZvlScEjK5xXYxudwrzr4236WvhXUQxAaYJbJzySx3H/wAdQ0rXkl5oafU+dZ/C15Kry6e6XaAjgHDcjI9j+dYEsZilZG4ZTgjBHP411OmaxNokaXllYxF1XmXcV2k5AbA4PPOfzrn7a1vNSuHZFaaaRizHOWYnknHWvXcb7GKOs+D/AImj8K+O9MvruUx2DOYLpuwikG1mOOwyG/4CK+x2GDjKsD0ZTkEdiD3FfC95ot7p9qs92qRCRtscbMC7nvhRnp74r6e+DfxA0TX9C0rQvPltdbs7ZLYQXcgJudgwDE4ADHGPkOGA6bsE1y4mm2k+qNYM9K7UtJ3wacM1wmglH6Uo+tHagBPrSjp2xQOnrSj8KYCjpTqBS0gEHWlxSilpgJ2opaVgEhlmkZY4YxukldgqIPVmPAH1oAbQOtQaff2OpMV0zULC9cclbW6jlIH0ViatMrIdrKVI6gjGKAuM7ZxS80cUUWAQ/rSdqXtSUAJSGlNIaQxMflTehBp59utNPJzQIbSH/IpxpDQAw0hpxpp4z60xjccdOf5U09acelIevSgBnSjvSnikoAYaT1p559eKYe9ADD1ziozxUjf/AFqYeOKYIafpTWp5phpAMNNbofWpD1pnagRWNIakIwSBSEUxkdFKeDTSaYCNwaYRTs+9BHFIkjYc+uKaeKe1Nb0zTEbCmnFuDiohT0OetMkkjOcV4B+0DqSPd6bajPmASSt17kAcfga+gU6187fG6y8rxbpVzLEfsk1kYtx7urNuGf72Cp/GnTt7SKYdGeQySSGHyvMbyyfu54z9K9f020ttPsBsMdvbwx7pGx2AySfU8fia8fu08pyByo5U+or3fRvCi/EDRr3SNL1+ys9Z8qG4t7KcYN3HglgWHIAwDxnpyACDXrRdotozep4zrupvq+py3TqVj+7FGTnYnYfXufc1lJMyuHUsoQ5DA4IPr9a1PFGi6n4a1KfTNcsprLUIvvRSDqP7ykcMp7MCQaxVBZVQev5Vi2M+rvgr8Tx4uNt4e1eGUa9Da5S6aTeL7YOcjGRJt577sMeD19Xxg49K+BoyyS71JVlIKkHBB9Qa9r8CfHXUbDyLLxdE2q2Sjb9sj4u0HGCSTtlx74Y/3q56uHv70C1PufR386Ky/DfiLRfFFu8/hzU7fUFjGZETKyxj1eNgGA98Y960+RXI01ozTcBTx1pmacKQDqdTRTwaAFAo70ooPHJ6UMDP1/V7LQNHudU1OTy7W3Xcx7n0AHck4AHqa+RPiD451XxnqbS6lO4s1b/R7FW/cwDthehbHVjyfpgV0fxq8enxTrhsrCb/AIktk5WLa2VnkGQZfcdQvtk/xV5PvJ75Ibmu3D0eVc8t2ZTlfRFoSKDuAAIPBHWvRvBXxi8TeHDHBc3H9s6apANtfOWZRx/q5fvLwMAHK/7NeXp91frUmTXRKCktSU2fa3gbxxoXja23aLcMl7Gu6awuMLPGPUDo6/7S59wOldL/ACr4Msryezuorm0mlt7iFg8c0TlHjYdCrDkGvf8A4dfHJJfLsPHXDchdWhTr6edGo/8AH1HpleprjqYdx1iaKfc9zPSm05GSSKOWGSOWCVQ8csbBkkU8hlYcEH1pDXOWIaQ0GikA3NHb+tLTaBh+NIfalpOpoAaQKYR1p5FNP6UANPGaaeT2p5ppHPvQA3tSYpSPekIoAaaYelPPXoKQ0wIj0/xph71Iaa1ADD+VNJpx5680hHPegGMJph9qeeuc0080CI29zTDT2Awfz6U00xkTmoialcVGaBMSlpMUooEIfemNz1p7D1prD1oEaIORxjNSL1qsh5FToenNUySwp4qhq+iabrFtJbalaxXFvIctHIoZScEbgD0PPUYPvVxScZPFSCpaTGmeX+Ivgx4Xu4mmgF1puwf8u0xZf++JN2T9GFU7Pwv4aJ03wL4sgvfDXieweQaN4mCiJL1dxeMk7sE/MMLuyCuAyk7a9B8baqujeGdQvmxm3geYZ6FgMIPxYrXhvhH4qpdaOfDHxPhm1/wzIAElPN1ZuM7XR+C2MkcnIBwCRlT14Nyk5K+i/rcUrHa+O9V1yPTl8LfGzQbe4tXYQWXim1jyIWJOGLYwCcDPCnC8q1eVePfhVrHg+zTVYLi11rw+/wBzU9PbfGoJwN4GdueBkErk4zmvZrTSfFNlonm+C9Vt/iN8PpU2Np15Iv2mFBj92Cw6hQoC+p/1YODWZ4ItfDcGq3K+APFEnh/U5i0d74U8Sxn7NPn5TCwb8RwXbB+ors5U/X+uhmz5z7ilHXmvaPHvwillluLrwdYXFvfwJ51/4ZmYPcWqn+O3ccTwk5AK89B1yq+MYwxBBDKcEEcg+hHakBZsby4sLuK6sp5ra7hO6OaFyjofUMORXvHw/wDjmjxxWPjlXL5CrqlvGM4z1mjHXH95Of8AZJ5r5/6UoNTOnGatIabR93WNzbajZre6ZdW97ZMcLcW0okjJ9Nw6H2PNTA4r4h8PeINW8O3wvND1C5sbju0L4Djrhl6MPYgivdvBHx0sr0R2vjK2FlNgD7faIWiY+skY5X6rkf7IFcc8NJfDqaKfc9qU09ar2s0N3aRXdlPDc2kwzHPBIHRx7MOKnGa57Fko5ry34/8AjH/hH/C39l2Um3UtUDRAqeY4sfvH/EHaP94n+GvTJ547a3eaZ1jjjBZmbhVAHJPsByfYV8XfETxPJ4t8XXuqEsLdj5VsjfwQr938Tyx92NaUKftJ67LUmTsjnZX5AHAHAqtFgSTAnjNSOeDVec7JGbsVB/GvRZiPVju6dGNTdqrk4cn3B/Spc/IaaAd705WKmmt92l9PehoD0b4W/E3UfBVyLaUPfaBK2ZrJm5jPd4Sfut6jo3fsR9S6DrGneIdIh1TRbpbqxl4DjhkbqUdf4XGeQfryMGvhYHGOfwrq/AHjXVfBerfbNLkDwyYW6tJCfKuFHZh2I5ww5H0yDzVqHNqty4ytofZdBrF8IeJtM8XaImqaNITHkJNC5HmW7/3HH8j0I6dwNmuFq2jNQNIR60tIetIYn1pvbv8AjT+O4ptMBpppFPpuO+KAGmm9KeevNNNIBpFJinUh9qYhh600jj2p5pp+lAyM00inN+NIaAGEdaYfQ1IRTeuKAI296Y3pUhphoEMbGT/nNMNPI4HSmn0pgRsM5qI9TU5FMI5oBkWKUAYp23mlagRGQaYetSEcelNNAiwvtUynAqBalStCUTg9AMVKvSoAfTrUyHkZ6E1LGeTftD6v9l8KpYK3z31ysRH+xGN7f+PGOvnCRsrjvXrX7Rl40muaNb7iVW3lnx7tKV/kgryFj39K6cJpTv3Inuamha3qeh3P2rRdRvNPusYMttM0bEehweR7HivStP8AinoWv20Vn8VPC8WstGNqanZ4huVX0IBXPXoGUf7JNeQqe/rTmXcOa61Jkn0xo8thHosOoeEPEOo6z4b0xxKjbd2q+G2IAMgUj99bnkSRY2lRxnBNTeLG8I+I3tl+KOnxaTqF4ubLxboh3WeoLnAJYA4bAAKuCRg/MoIr5u8O69qvhbWYdT0O9msr2I/LLEeo67WHRlPdTkGvoHwF440vxQtxbabYaVa6pflWvfC1+B/ZurSjnzLZmBFvOcYwcqx2ZyRuF/Ev6/r+te4HHeLvgh4l0i0Gp+Hng8U6I43R3WmHe5XgZMYJzzn7hfpzivLDwSDkEHBB4IPoa+lPD+lWsOuXEHwt16/8E+K0INz4V1vJglbA+5u3bhjcQw3EjkBRzSeLtU8N6verp/xv8Hz+Ftdl4j13TRujmIAyQ67t2AFXB8zGedtTZ30/r/P5AfNnNKD3r17xZ8CtcsrL+1fB15beK9EcF0lsWXzsDr8gJD+nyEkn+EV5FKjxSyRSo0csbFXR1KsrDqCDyD7UXuBv+FfF2u+Fpp5PD2pzWJnAWVUCskmORlWBUkeuM8n1rsLP42eOYHV5L6xvF7x3FhEM/igU/rXl/vSMWxjJAqZQT1aC7R6v4w+NOqeJPC1xo0umWlnNcALLdWkrgFM/MoRskZxjO7oSMc15UI2Y4XBPcVCT+8IxwBUjyMgAXgnqaUYKHwoG29xHV1J3KwGPSq0zbkXPTkVeV2CZ7gZpCiyJ84B78cVTAz1YtwepXj61IW3Rj0JFSNZtuBhYEA52txgVBh48LIpUg9xSTAt54xQPuD2pgNPU8dKuwDuozS9E/GmjoR6UrnhR71LA6TwR4s1LwjrcepaRKA4GyaF+Y5485KOPT36g8ivrXwb4p03xjoa6npDEAEJcWztmS2kx91vUHs3Qj3yB8TA4rofBninVPCmrpqOjXHlTAbJEcbo5kzko69x+o6gg1z1qPPqty4ysfamc+tFcz8PPF9t440KXULS2a1uLeTyrq1MgkMZwCGB67DngkDkEc4zXS849a4WrOzNbhSH60tJk0hiHtTT1p3emnOfegBDTTTvzppxkjuOo7igQhpD9KWmkdeKQCfWmnvTjTT0pgNPSmGpO9NIP90mgYw00j1qXy2P8LH8KBDIekb/98mgCuwppqw0Eg/5ZuPqKjaNlzkBfqQKBEBppHp2pzsifflhXHXMqj+tVpb6xj/1l/Yp9bmMf1pgSkU0/SqcmtaPFnfq+mjHX/SkP8jVZ/E2gL97XNO/CcH+VAzUIppHoKw5fGXhmM/Nrdp+G8/yWoJPHfhZSR/bEZ/3YJT/7LQJpnQ46+tMI4rmn+IXhdemoSv8A7ttJ/UCqknxK8MpnEt+/+7bf4sKLi5WdsD+FSLURIU/O0a/VwP60ongX71xbge8yj+taGZYFSIcEetUW1HT4/wDWajYL/vXUY/rTP7c0ZfvazpY+t5H/AI0rFI53xj8ONI8VvFLqJuPtEKGOOWGXy3VSScHIKkZJ6jv1ryXX/gdrVmJJNJvra8iAyEuB5Eh9s8p+JYV703ibQI879c0wf7twrfyzUX/CZ+Gk/wCY5af8BDnP5LSjzQ+Bjavuj5C1zQNV0CYRa1p9zZlidjSp8j/7rD5W/A1ng8V9g3fi/wAGTQyRXGowSxP99FtpGVvqu3B/EVwniLTPhVqwZhHLbzH/AJaWFs8B/IDZ/wCO1tHEtfEvuJ9nfY+eCM8HkVEVaM5Tkeld54k8JaTBmTw7qt7Ouf8AU3toEIHtIhIP4qtcjcWN1bg+bC+P7y/MP0rohXhPZ6kuEluj0rw58TrPWNMh0P4m6c2vaXEpW3v4zt1Cx44KSZG8A9mPpksAFr13SL/Wz4euI9EvdN+K/gwD95p93hdStlyxAYMCWwQMbhuOBtCivkwp826M4YelX9J1O80+9ju9NurixvovuzW8hjdfow5roUlLSX9f18iT6S8M6Jot/qc1x8GPFd54T8RqxFx4d1bcFZhkFSjbicAMT/rMZH3ad4s1fRtWni0348eD59A1Zh5cPiDTlJjfjPDruzgbRtPmAEnIWvO7T4r2/iGGOx+J2iw61Cq7Y9VtEWDUbf0ZXGA2OuDgE8nPSvVtH1nxFFoU0ujz2nxU8DMcTWdyobUrZckhXRgS5BweQSdvAUc1Uo6Xeq/rr0+egkeZeLPgfrdjZLqvg+6g8WaFICyT2BBmAHHMYJ385HyEng5AryV1aOR0dWWRCVdWGCpHUEdjX0x4W0bRtTu5r/4G+Lp/Dmt53XHh7UyfLYjggxtuPA3HI8wAnjbTfFmo6BrNyNP+OfhGfwzrj/LFr+nITFNgA8SLu3YG0YPmAZOdtTZp2X3df+D8hnzMq4dqVx7dK9j8UfAjXLWzOqeDL6y8VaMwLJJZyKJsDOflyVfHT5WJJ/hryW7tLiyvJbS/hmtbuI7ZIJ0MciH0KkAg0lbYCEfd+tOXpigKQPXNLjj3piEBwwIqcMCuCB+PSogP8igEdKVgHmGFhyCp/wBmo2tSo+Rw3oDwakHSlDEHinYLlZlZT86kfWkJyVFW1kOKR0jkOcFW9RSGVqfH39Kc8LAErhgPTrUBYqCo60nYDS0zVLvS72K9066uLS8Rv3csDlHX8R29q9h8N/HTVjrVnH4jgsJdNI2XDW1v5coO0gPndjO7BIxjrgCvD44JGO4jA6Y70piYkhYmJHX61nOEZLVDTsfWknxO09WIXSr4/WRBmoX+KNov3dHuD/vXAH/stfMdnqV/AuwXE8KgfKiuQKv22u3ttvPnmTd1Ep3DPrzXM6HY2U0fQr/FRf4NE/76uv8A7GpLfx/qt9aRXOneH7WWCSbyA5vDhT3J44A9a8L8L69Dcaqlv4juza2EoZTcxxbjEdpwSADlc4zxXrnhy1uIdNtrfwyNOutJlHlXF7bXCmXzFIPnbT69NhOQCMdK5aylT0OvDUoVbt/8E7W51m7ltBkW1usreWS4YNGcZweev+NZEmpXmnOJ7Z0WeVdjNPEWR++QNw9PXvUQ0+aZLldR8qcylSYgmEGO/Pf3+lVRpkMV5l57kMABGJJAyoM9Bkfoa4va66s9VYelFNJbksniXxI0zLHf+HVUdCYnBI/3Tn+dYmr+OfENncCKLULKc4yxis1G0+nOaoeJND0nQNN1fXJbd72QnzFied1SPPBCBSMZY59u1eIfa5duGuJG78uTXo0Ye1V0edilSopRUdX5nstz8StfiBMuqwRD08iIH+Waz5PinrDHA19lP+zCoH/oFeTGTd9fWk3Dua6Pq67nn+08j1tfHniG6U+Tr1xJ/uOoP5AVBL4r8Qufn1rUP+/7D+VeWBwrBlJDDoQcEVoW+tXUPDOsyej9fzrKeHkvhZaqrqjuZPEGsuPn1bUD35uH/wAarSanqEn+sv7xs+szH+tZFpqdvdbAr+XM3Hltn9D3q3tLHnvzXLLmWjNU01oOkuJnJ3zSt9XJ/rVeQ7hzzn1NSVFL/qnwcEA1O4zW8PeGb/XllkskiW3jO1ppThd3oMZJNbU/gmK20N71pJJ7mE5liChVIHXb349/0rb+GM5g0C0A5ibeGHvuP/1q7aS1RmJHKt27Gs4tv3j1KFGmkm1dnnWgwQ6LE7RKYobxGeVpDv8AMXYQiJxnliD1rKuvCNxf3saWIghuJBueJztC56kYz+VeoT2MbDlFAQBVCjAAHTFc14k0Vr21kNtcSQXBUruX/PrinFu9joq0ozhZLQ4PUfCmo2c7wwyW15Ig3NHC5EgHrsYAkfTNYU1vNE5SWN43HBVlwQa9bmtprnQrGecFb2OSNl5yV/vjPoRnNYniWyS+sysg/fJzHJ3U+mfSlztWutzinhFrys83amHnH9KejAs0bYMwJG0D+lG1tx+VyRwRtPH1rY4JaaMAF7qKcAnGVWmAjvSjINXqZk6hR2H5U8FccAfhUSnOO1PUg9OamwEoPH0p2Tn/AOtUQZemf1o8xAOfzLdaBlhWzz/SpVJPeq6uAMk49zTw+eB1HJHpSAsqcUjIj/fQE+vf86hLMoBKnBHUKelSL5m1CscjCQ4QhCd3096LAnYpXmi2d0STGN3rjn8xzWDfeGJEy1s545Gef1H+FdVGS8uwBiw6gjbj65qwhyu5QSPbk/lVxqThsxNRluebXFrcQczxFcfxDkfnVrQdb1LQdRjv9GvrixvY+BNA5Vseh9R6g8Gu5ubJbkhWA8xhnhlOfZhn9DzXM3fhuSZg9ou3J553KPcgZZR9RXZSxlvj0MZUl9lnoNt8QvC/jQwJ8TtIkg1ddoTxJowEVwMbcNIgGGxjqA2B91RXpen6r4103QjJavp/xZ8DzLscBQbtBwdsiEMWbLAkEO3HO2vlW5t7izbbcxlAejdQfxFanhvxHq/hq/W+0DUrmwuRjLwPgOAc4ZejD2YEV3xnGa8vw/4HysY2aPoXwxZ+Btcv/tXwu8W33gXxGzgSaZct+6lfccIYnbDknHCsQB/BW34m1HxJZaf9k+L/AMPrTxTpUKkf2xpCCVo025Z9hAZDxyw8sDFeYp8W9B8VRRwfFLwfaanKAFOq6d+4ugAOMjIzz2Dhf9muz8F31vGqR/C/4rNFtVBHoXilMqefuK5AwOvEYJ9+9U4N+f4/juguYb+APhf4zbzfAnjRNGu5MY0/UskbiOEXzCr5z1IZ/auZ8RfAvx/o7yeVpUOqQIu7zrC4Vs+wR9rk/RTXrfibS9Wu3ll8f/CDS9dBbdLqfh64AlceoTiVj/wKuY05fAK3r2fhrxr4u+Hmq+ZgafqLSJDGf9pWOMf70lZpX+H/AD/yYNngOqabqGk3n2TWLK70+7wG8i6haJ8HocMAcVAox3r611F/iPp2lhfEWiaB8S/DTZlEltGgnZP4W8vG1jjnCK5/2u9cIPBfww+IE7weD9WuvCniDJX+ydSU7S4JG0KxzuJxwjnAH3aFf19P8gPCB0oz613Pjb4VeMPBweXVNLe4sUyTe2OZ4QABktgbkHPVlA9M1w4wygggr7UJp7BYDg/SkHHtS4oxzTsAm/Ckin4Vzlhz0z3pjDCgUozU2AV0eJS0TlvVTTYpI5UYogEgPIzin54P0qC4G4CaLPmqMn/aFJjJHbYRyDkHpTpDlMDtVdzuwy/dcZFS7unoRUgAbH3q6b4d+LJPCfiBLsh5LGX5LqBTy69mH+0vUfiO9cocjOaTPNTOCmuVlwm4NSR9i+H76y1zSzqFiyzwGTYsgPDcAj6deh5BqPXIFaF9gAYDjtg15N+zXfH+0dd00udkkUdwEJ4ypKk/+PCvZdUiDwsB6YrwK8PZ1HE+iw9T2lNSPmz4k+MJ9WnfS490drbuRLngySDj8gRXCZ5rpvibYvp3jXUlZSFnYXCZ9GGT+uRXLA8V7lK3IuXY8Gu5Oo+fclVuPekZz9KjVsAk0hbNaWMRxY5NIJCD7UwmmZxSbAuRTskiujFXU5DCu68NPLrdtLsVHuYQWkRJMNt/vhMZI9cZx3A615yW5q1ZXc9rcRT2szwzxnckkbEMp9QRWNal7RabmlOfK9dj1GWxhT91v3M67klBOCf7oU9/zpIdN/tGdLWxtpJbllOIVbczHHfn5QPU1oeAPFuja262GvafZRag5I83YFjuG+nQMfToe3pXr2nWsFkpW0t7e2DkbjEm0t9a8mcpRbi1Znp0sIqiU1L3Sj4f8Lro3h22s3YNLGpZ2ByNxJJwe4GcVct3KKY5O3AzWmk6qu1uvYjpWTqioQWjYA+9a0UmlE77cvwkd7OijYOWJ4rJmcbjuIHfGaRZUM23duc8Adcms27NyxEkERKNnaxHBx1ArVwWxSmzUlkwgQcA/oPWvN9X8QpJeToufKUkIc9cVRv/ABRPIlyvnMAWZME9PasBf9Mlj8rJ2uAx7etKVH3bnHLFLmtEbCrNrKuv3sM2AM5bGa2lO6RwVOHUEkOo2cewPr6A1kLGft6FcN853AnAI/zmugdGa3iErNJMeeeQFz/e6EfSsmnF2ZwVmnK5mvZR7wNmwdcnOc+6ntnvSrBCjIJEQxnPfK7vZl5/DmryZWIHazB12YQYyPUk5A57Y/E1NDBhQrlpYgx2vEwIyO7KM478kGtTmuynDaxCRUKR71GfMAVkI/T/ABFOjgEqbZEAuNxkAZCRIvp6jpWjIv2gQAjfFL8jOvzehOM4/AZx7Gklwsrm7DW8UYPyuxUycH+Ig8Y7Z9KSTei3HfoVo4R+6K7ldv8AXKi54HsM49KdHDtjlkQFoJCY4WXqvHAGSNv5c0/T71byCcxb1lD/ACKVDAAjqo7Hjlqt/ZjJ5YhikjdCWUA/K3HUswGO3J7CnOEoNxktR6rRlPy/Lso0fG2BgcqrFWOeQGz+fT29afcoVAmfzAjkCKVGGBgY5wQSR6HirykeWqMhhhlJOMHezY67gAGB+vpSPG6F5B5ouIh8sqcr0/2eE/DnmpEVUi2zsHgEe0bs5RWYnp8w4Xr068j601o5DHKXj/fnH7pjuyCP4cZJPbNXUQ+YqKyO5PmfJIGVeQDtJJGTjuRg4xUkjhtvlRurr92Pfypz83UYI5IzRZhcqpCsnlgLK8MIztjJbLjsf7o7E4oSMok8atA0m8bJF/eBj7HGSR0z+tTTRqRL5brs3bnkCMYwPoVJVz3wQOlSoY7iePy0R0RVJCzHzAFAztyCePQGjlGRMplcGYosezMnm5BjYZ5Dc4OT0B9KrwwyAgSRv5iAv0y7Dv8AN/Dnnt0qzM6yRkxbWMTAmAqVK9TyDxkc5+v4Uspt/slzdGa3Fp9+ZncgxdAMYAyT0APPpQkFyu1pBdITNLGochlfZwRzwB/GenJxVU/Di11G3lmhZ7FuFiKp8rEdSy5IPOMFTUPhnUH8SeKY7aKeSDRbX94UZt7yKoOF56Bv0HevRJ9W8iZldQIuuMgbPp7dOK6oYWrFc8dDSjOm5WqbHhmu+EdX0ZnM0H2iBeTNb/MoHuOo/Guf4YDOCPzr3O91UfannXcSw2pGg5/H3PtXlfiiyiPiKCKEwWslw4EigcJk4BYDp1rui5xV5LYitTpx+Bj/AAz408SeGGU6Brl/ZIrbvKSYmIn3jOVP4ivTdO+PEuq2Sab8R/DemeJLDp5vlLHMuerAEFd2Om3Z9a8ZvrC8sHIvLd4wP4wMr+fb8arBsjjkexrX2imrvX+u+5zONj6d8HaZ4c1Oc3fwW8c3fhjVZcltC1FvMjkbbwPLcnPQksDJjPGK0fGt1FcW/wBm+OPgUoE/dx+JtFBkiUZKhmK/PGvOQrZyf4O1fKgbp7V6P4O+NHjXwxtiTUzqVkODa6lmdcYxgPneAB2DY9qbSlrf7/8APcD2Pw7p/jTR9OW++EXjKy8Y+HkI26ZqLqZYgeFTcSMYHON0fT7prG1vWfhv4o1F7T4k+FdR8E+JJBlrqONow5J+/kLhyTn5njIx/FWLZ+K/hj4ivV1Ax6v8PPEODm90dyYGOMAEIOh6nCLnuTXoqXviq50NnkTw18WPDKfM3lLHFeIdueY/mQkc8D5zmlKPWX9fNafeFzzTVfgNf3Vm2oeAvEGk+KLJeNscqxy5z90EMYyQOTll+leV6/oGseHbgQ6/pd7psjEhPtUJRXx12seGHuCa9vstJ+Hepa1IPCuua58NvFSfL9lvi0C54yCGbvnAUOP9012NxdfF7w3YPDr+jaN470ZlzN9mwJmTpt27Ru9eI3+tS7rr9/8AnsB8lsKXtXvOo3HwY1q8lt9d0bXPBOrA5mRYXjCt3URgOoH/AGzWqGofA1NYtZL34beK9L8QQoNzW0kipMgP3RuUldx9GCU3datf5feB4seVxjrVdpNgVVznNbfiTw9rnhe7Nv4h0m70+TcVBnjKo5H91/usPdSawXGWDAHipYA2RgAZAbj6Glz8mPQ0s3yxL6Dr703+E+4pDBjk0wnoaRjTSeBUjPRPgZf/AGL4kWCk4S5ilgb3+XcP1UV9MXIGOAK+PPCF9/Z/irRrvOBFdxknOON2D+hr7CRg8JPccV4uPj+8v3R7eXSvTt5ngXx/08pdadqIU9Gt3P47l/8AZq8hzX1F8TdD/tvQLq2UDzWXfGfRxyP8Pxr5ckDIWVwQykgg9jXXgKvPT5eqOTMaThU5ujBmycZ4FKTgc0xKQngnpiu484cajc5O0U7OBntUYPBPekwFLfMcfSlBPQHpyTTQD27U4YVeQcetIZKHwOcN9O9en/D34irYW66X4gupRCh/0a7bL+UP7j45I9Dzjp06eWb/AEI/Kl3K2A/HoaxrUo1VaRrRrSou8T6ml1cfZ45BMswddyyIwKsOoIx2rltX8UNEWBJYeo6ivLvC/iWax0qXTZWZkjbfCeu1T1X6Z5/E1Fd6yZpNsYYn3HFYwpOOjPYWKg4KVzvLXWEl1CC5guXEkThwCDz6j9a6zTZoHuhd208NtPJHt/4987m4AGMHnA56HivDIPEcttclVOQOPSnN4w1MTmSzvLi1bpvhkKHH4Vbp3uTHHwjuro6D4sWFvonjGVLR8LcRi5kTpsds547Z+9jtmuc0q9eGT5SeRk/hWHcXUt5dNLcSvLK53PJIxZmJ7knrVu1cjcwGc/KoA61Un2OByU5uS0R12kXQM3mBSzDO4g46jHBrZSaJ0CqoITlWZlVlPbHdqyNHtGtbQecP3r8sPT2qzl4y20kZGD9K6fqKq0+baRTp3RsjCsJyriR5CGK/KW3dgfX9frVkxjdKJDhhHkxsuHVSMZPYjAHU9xxUkqyLPbyec0ZmXI3Knl4A52n17YA59qzdU1G3sZ5Y4sysckRAYXcerNyTjHbP0rgpUZVZcsFqciTeiJ9RntrKOGR5TLA2SvyL5hb1zgZGDXOXN1NeyfPlIQflhX7qnpnHrTP3lzKZZm3yN1NaVlaZI9ete7h8JGgu8u51wp8oumwujq6Eq68gr1Fa8SlBkErgY46Ee46H8c0scQUAADA59KnUY6c1pOnCeskmaNJ7oTdgMqsyh+WCnAb6gcU44ldWkAcqNoDKMYPt0oxz/M04LgY6+4rL2FL+VfcJRj2JFmdUVWfzFXG0SAPtx0xnOPwojdwfkO71LfMf1zTAp5zinqMD3o9jT/lX3IfKuwzyQuwhcFeQfQ1Q1rWLXSmSW+eVp5gdoQlnYD3zwOfWtQgKCWbt6V5Z4jnu73WpFuvLjCsVTAwqr29z2qKijC1or7jKrLkWiN+58dCOGSLTrV1Vucyy4GfUqOv51yGo6pd6hIHvrmScrwoY/Ko9AOgH0qUWNv8AMJJpSR3VcZqjdW5iyYnLD0YYNYOV9bHJOUpbmh4b16bQdXivYV3qBtkjzjevcZ9a7fUPiJpUqh4bO7aQj7hKqPzry/y5COcD9f5U9LfP8TA/7uK0jOSWiIsb+p+KtS1SYxWg+ziQ4Cxcuf8AgX+FY11bG0YqzZnzl3znBHb6g9TT7MNbM0iMpkxhTnGPepJle5++URB1C5JPoP8APuamUnLVgl2PR9N1Br3TbW4YEmWMM2e56H9Qaq6hpNheqd9siOf44xsIP4Vl+HHe30yKHByCWO4dya2VlkYf5FdvJzL3kegnzLU5DUfD9za5aD9/H7cMPw71jNlWKsCrDqCORXpBZ+nPNZ1/psF7/roxu/vrwRWMqLXwmE6CfwnELV/RtV1DRdQS+0i9ubG8T7s1vIUYeoyOo9jxVm80KeLLQESr6Hg//XrJdWRirgqw6gisruL7HPKDjuj2ex+Nia1p6aZ8TvDlj4ms1Py3KqsNxFk8kYGM4x93YeOSa6TwxP4PedZPhr8StT8GzPukOl6sPMtw3YfvDsz/AMCc1850oP40016en+W34En15qmofEmx07yPGPgvQvHmjbQ/nWG1mfPRvLZTuP8Aux/jXBxxfCDV9RHlS678PfEMD42sZI9knrzuCgH3jrx3w14v8Q+GJA2gazfWKht5jilPlsf9qM5U/iK9Is/j1qN9bR2fjnw9onieyXP+vgWOTPqDhkB+iihJbx/yf+Qj1m1tfihp2nb9C1zw/wDETw/IBGEudiSSL/F84O1vTLO30rh/Eug+A77zP+Ez8Ja58OdQZyv2u3iMtg744UFVKepwqr/vVj2F98KdQumu9A1nxN8P9TKgboneSEknnlSzY/4Eo9q9D8PXXxEhV4fDnjjwf44sgm0W93KBOy++3nP+8xpSh1f5fqrr70F0ecXHwEk1KFZPCXjjw7rNuWA3MxjK59dhk/pXkOt6ZLoutahpVy0Tz2NxJbSPESUZkYqSpIBIJHHAr6W1rQobgCTxL8B2WU9X0W9jO4+6xFSB9c181eI1ji8Q6pHDYyadEt1KEs5Sd9sA5xG2ecr0P0qLK1/1T/IdzMP8qYT06UMeeDUbdBjpUMZK7lUDL94fMK+wvCWorqGj2dxkETxJJ1z95c/1r44Y9PpX0n8EdS+2+CrSIn97as0PPscj9CK87Hx0jI9PLZ+9KJ6FqEAeIjHbNfNfxg8NvpmrnUoI8Wt037zA+5J/9fr9c19Pn95GK8V+N/ifT7aGbw/apHdX0gAumPKwDqF/3/5fXpx4RTVX3Fp19D0cZ7OVBqo7dvU8IZsnHb0pGbsOnpSvGc/KM5p6Q45c5r2z5wjLFiABT0QfxHOO1SKVXgACkZs0CEY8nGRUe7IOfzoZjjI7U3POO1IYhNJmkzTSR1qbgTwSOsqNGu5sEbfWlmWcyblRk9s5rY0TTG8vz5uCw+Qe3rWodPU8tn8q6qOFVSPM3Y6YUZNHGSRylmbY2Op4qMbuwNdm2nx5wB3xTBpyj0/Kr+of3vwH7CRzNtayuQQuAfWuj0e3FqRIQGkHQnt9KtxWKjGcD6CrsVqgHU5xVrBQjq9TWFJxJYJiTxk/WrYG4A4psUKIOF7VZCDjGev51ryWNOWwuo6x9neVdPZVnJ/4+IMxhR6AHnPTmsIRs0hdyWdjkknJJ9Sangt88AY9/StWysTwWHHrWtKjCjHlgiIwUVZEFjakgcVswxhQMfnT4oQg2qAMVKqnt3qmMaM9MUoPYHJpxjzweR6Uqoc8ZqBidO2M0oJ7cfWl2d/5Uu30osgEBYdOlAYj8O1LtJPGaCOSKLANd2IIrNutPgnO6SNGz6gGtIoe9IUOOnFUtAOek0e1OSbaIn121XbS7ZOVtovrtrpHjJP3Sec1XljOPumqiop7ILGCLSIH/VIM/wCzTXt4xwI0/Ktl4iCeDUDxtn7tdCkVYyfssJ5aNPypyW0KnhF/AVomFieFpv2dyfuiqutw5SOAqoAUD0qysoHpTBA4zlc08QsB0qGkxWHebnIH0NML574pwhOKTyzn0qOVCsyBwCcE81UuraKZcTIrj6VoGNqjaAt0/Kh04vRkuNzmLvSFBJgcr/stzWVcQSW/+sHHqORXatbE9qqXNmWU5XIPtWbwUJfDoYyw6exyG4etG4VtzaKDkoGU+1VW0WcE7WB9iK5pYOrHpcxdCa6GbuNGRnOBn9a0P7Guf9mlGjXHcrj6GoWGrJ3SF7GfYtab4v8AEelxeVpniDWLOL+5BeyIv5BsVjXtzPeXc91dzST3MztJLLI25nYnJYk9SSc1pDRJv4nH4Cnf8I/KW+Z2x7LVSw1eW/5gsPPojDYioycnFdXFoAUf6sEju1TNoeVBdV46ZFUsA2tZI0WGmcgsUjMcI35V6v8AATUJLTXLrTJThbpRLGP9teCB9QQfwrlJNNaMZwPaoSLm2/fWcskFxHkrJGcMOMHBHtmniMqjUotJ3ZtRjKhNTPa/ih8S4/D1vLpWhTLJrbArLMvK2nr9ZPbt354r51lkZ3Z5GLMxLMzHJJ7kn1prMe5JzzmoicnrgDvXlU6caUeWJhXryrS5pAzZIJNLvzjPcVHuzk9KUHkewqrmArH5jimMc0hbqaaWxSAcxyc+tNzzUqwSyY8uJ2z6Cp00q9kwBA4z6g1caU5fCilFvZFEn3qS1hM8oQD5e59K2YfD05UGZZAT6DA/WtS10gQJggIvfJrqp4CcneeiNoUJPcl04NtGSdo6DNX9ntTra3RYmKkFV+8QchfrjpVq2QXBYWwaZlGT5SFsD3wK7nGx2pqKs2VFhzkilEPrmr9vA9w7pb291M6EBhHC7EfXj9KFjkKMywS5Q7ShAV8+mCQTWbnFbyX3oftI9yokXsc9qsRx9TzVmK0vGi81rKaOA9JZMKpz2yCaUQXIt/OECAE4UPMql8dcD/HrUSr0v5196JdWHcZGmPSplQ5wO/bFJdQXVvszHEXccJ84P6qAfzqS1sr+SN5J3tbSDjDyK7bh68Cs3iaPWa/H/Il1YdyOws14JA/GtRFAGAOOnHpVZLbUpUU2U+nzEgEgRuNv4sQD0PSltINWuLhoIr3TFnBICmNmLHGTjbmqljaH8/4P/Ij20C4oPf8AKn47Dr61Qit9acS+bNBGydcwKOfTDODn2696ht/7Sn2Kmp2QZu7wBUHrzuJyPTFL63Q/m/B/5C9vE1R1+lPA4znn3rMFtqzSMkeq2EgxlZFjVEJ9Mvjn2oihvpJjDJrFt0yZQECKMZ54P6VP1uj/ADfg/wDIft4mhnJGevSnrgdgaoxabqMkpVdd3womWljsyQDnpgA44wc0hs72SZ0XVwiJxlsAyH/ZG0HHbOM0vrlHv+DF7ePY0SQBx/Kozjmq9vYySqVl1TU/tO7atskCkkYzu3cDHqOCKbJpsqRkvf6sZlU5SJI3Rj0yGBPAP44FH12iuv4B7ePYuBT6CkcgLx371VfTGj04Svq6zu+VVY5xuHpwBj8D+dTWOhB7Fpbi81x5VYkmJE8sqO25uhHOaPrtBb3+7/gj+sR7Cfh7YxSMBg8EmjTtFW7V44tQvJ7xSWWFR8xXOADkgL2OeaV9KslRormXVbW4jUM8gn81c5HGFHp3yPQU/r9Baa/cv8w+sR7Ecig8sOKgK55FXk8PQRSZvZdXWORsQzSOI0OFJOQRz0PcHHY8ZT+ytNFwqXU000JXcr6fMc8jvuJ468YH9Kf9o0el/uX+YfWV2M8ICOg4FO8rKn5a0RoNrFdEaqb2BDzFEM7nGTycHj0wfTt2LzQbexkKX2l3RaTmELeMpIHDEqC3PI7nvR/aVHs/w/zD6z5Gb5Z6bTk/hzTwinIOc1qXOi2likANu8glYL5M4AVyeo80HIOeP4SMehq4/h/TFkGbWEpv2jy7wssYXIJkZsjGcEcA/Wk8zpdn+H+YfWfIwNqYwMfUGj5Bj5lA+o5rYfSLNoZRc6fDO8IaQTrOiqoJGONvzdvXr24pLrT7I+RJcw6RFHguVsYR5hyODjIHt1P060v7Th/KxfWvIxy0XPzRk+7CoHntkyDJDjkcsBXVz6dZW620Vva6UqzKW8242Oy89Sy9B06YOKtQW0dtHFHpkcTBQTLeKC6qP4iV24PJGMZOPxqf7Uivsfj/AMAPrL7HDyT2gJJng45PzioXlttv+uhx1PNdjavCsjxwzW0u9tzTNDFGqnoDllY9yMdB1qRTDDp08Fxc70QbYRbmNwBg5DMFyPrwKX9q2+x+P/AF9ZfY4lkj8sNtIQjIbY2D+OKkksXSD7RJbXCQcfvTA4XnpzjHP9a7mSeW5t1YarNPFhS9tIj7TjqpYZ98evqKZBbyXtrFLbyQoUyTFE85+UDJGcsCcKeB/wDqP7Wl/KH1iXZHEwWhnYLDbzu7AkBYHycdT0pz2kkMojlsrlJDghTCc898eldpfyQXkETi4+ztFI4KTzSSEdOQMHb178+9QxzQXEJivJ4bSOGTegtoBlhz8wbJz0PqelT/AGrU/lX4/wCYvrEvI5U2c0cux7SeNtob548ZH51KunXmT5lpcQovO+Zdij6k9PxrprQWxeRJ70z2avthEolKk9M/KcA/XJ4puoZ+3ncVS0XnDNNsJzkA7hkHPrn6ioea1drL7n/mH1ie5zaabeyyyJBaST+Xyzxuu0D1znpx1py6ZcMMbIVuN+wW7yYkJ7diP1rprm3jN1DaNaWccYJdzZ4UsR3DMQq5yOMk9TUmoE6bHHDBaLDgsG+0LHKGzzy/P+I4qXmlZ9F+P+Yvbz7nLnQ71lYywQQFeonnEZP03DmsqXRi9yI2Aj67iMuAPoBmuxuYU012V1s7ubdyHVzt44xyAQR06k1K73enZFld2qi4fzPKtQWK8EA/MCRwDyTn2701mldbNfcS6031/I8V1bw7cwXki2TpcwZyHGUx7ENj3/Ks7+w9TaQILVixIAAI6npX0BeQTWlvNMby5DTj96FiQAnJ4ZgTj8OvNUpIYLewjdRp93M4Bc/Z2EkeTxz0GPU1xyruWphyniP/AAjuprKsdxbNbscf675etX4fCk24G4mBTOGEADMte3+VFpcSNOWkZ1AbbNFKrDOfl3DKrk1BA0cYkle9SZnBUtayPGIlAxlgBz7k+nfNT7V22Hy+Z5lpngxN8hMUcyocD7TOsJ9jtJ9+lbEWgRW2n/vYvLlwSGFple38e7B/AGusa3dgjWBFzD1eY2mTGegDMQSeP4h+VOuxCLSNIHuhCPlcRSOybQc4UMAv16D0qliakfhdvQa0Ofj0e3trdmuSl2XICiC5aNou/Kkcj2FOisBaQ/K9vLbkgPu2ytGcg4YHvz0FdHcRLNa2/wBmtZViiGGm+yKXwBwwI5+pP51HK010ySOZPKQ/JLFaopVhyBwcjqOST1x6VDxNWS96T+9j33MqK1tBIU00wPLJuMv2u2REVgMjaCME9ttXotNgVY7axgNxfIN6NFIssaccghgBnqcDPXip9QuBPPCf7Ta7h835vNhOxGxnKjGD+H5VSuH8u7Sa2ltpRGcBoYCibc9AoHPTk5rOUpPdgTQRyvN8sWqXIiG2REURYfrg7T8x68H9KjuYdRMMYa2aC1DfujPEpaNs8ANjdnPenajtlVpHubaQqdpW2R0cjgbQduDx1/xpl+9rHZxoq2bshK+ZC0mF46YfHPv9eKmwXJfKisCYkjlurw9Aq7hg5+4ynPpknsKqBPI/0eTaZpehubdV5I52uWyCTjk1fv0keyjlme8dUVHMf2QKoGPuh8e3UHvVN2t40M9utoAvBRXeTA44G4cHgdMdTSWwMrtbNEyWyRQzO/DFYkk9yqEEn61JqLSWVsLVbi5yfkKuHiXjkDBByOnelXzTN58MJvNuFeJLMhBgcAAYGelOubaK4UzW0lu0kZ3PDbxzYA9MnIByOvrQA2SciaGaW6cuvBWIukpJHOCQePXp06c0QQMEIl0+cW0hyWuXcYOeGDL2z3xT7wXN7bxXEULLbxnJBnEpjwRx5ZGQfzpLuUXkLpZsJJ22Hy7W0KbBg8ZzkH6daErgTywJNemEWSteoQQZWXysBfvbQOMAg45yfWhY57q7htVW1nkaPzNsSeQCM5ySAD26UUVo9Fcga9u6alEslraKzAPmQtIrk8AnJzxkdseoqyfteo3ccVvJY3RTcSBCUjHI+8Dy3bt+FFFFtLj8isWiInN7aRny2MT3CyeXHHxwNirllGPTPtVqJ1W1kjRjqEKNgwlfKVQACOc5bt1//UUUPa40NezSK3S6ijhlBVR5flkogPplgcYPTFV7OOC4YyxH7LKqeahjfZwO67Uyp6/lRRTjqD0ZNOGurXfe20flYXN7kvJtzjdgsMk9Px6VHBeQ26zQm+vIrIjYwjRcjJHUfj1HPFFFOCvcTdghuLZLSS3lupfs2MARQJvIOG3MTjIB7daklWOF3Md6JYMkx28xcnB53YAC9yduSKKKfLuFy69qTpK3V2mD5eYxbsI1jBxhsAZzjtkjjvniKzhMtm6i41IQO2Zirr5e8cfcyNx7bj6g+1FFQ3ZFWLltp/22SSYW1xPCUy0M84yxwPmUjgcEHB+nrVeG6iWyeGG4eDzGLCEWyMFHQfNnOeoHUUUUk7tg9BIpYooZxqcIDIpKqI1Lk5yzmQZYE98H+KmQ2AODHLCQqmUxFcSFSDjLBcZIPUEe4ooq4e8rilo7EkaPcGS90jTkhgKsrHerhl45Af2B4xUtnbtcq8OkpcywA7p4Z5QiSbe2FII4x0oorPm0bKS1S7if6PBeD7VFaWU6MXjhjtzKH9WPzAHH1B+tPtH+06pPcQ3VirFCilIXCnP8SjAwcA5znHYmiitVG8bkt2diMzLIZZJLGzmijbEk6RkFVA52qWGDge9S2di95bqNLNwI0bewuJQVLjByqjjnvn25oorO+rKSu1cfcTXWos9jOq7ncgxwIq8jkjcxPYE9D061Cbq4sWmsL2NrgJGB9nMm1FA7kDr2I5ooovrbyF0uOFwYktJLG7UQudzWduZEUg5JALDvyOatvBeCCC6ghi05C29zDMSZBwOVxyRz1IB5zRRVTXLawo6ma13p8dy02ntM10o4FwgdJPfHrxnnA9qu6vY3phZ55rVjGACkKFCVIA+hHPQ0UUSVgTuMu76Cf7MrXt1PCygTMIlVsDJ4J5zkf/rqKW6jnuoEbUrhkhG5jLEG2MBnnGA3cdKKKFG7sLmZM0dzf3iPHGmp2qgsp2rBjjP1A74B7Cs+Z4ZrtZYwln5Z2ojMZPqQcHGT+PvRRShrJxKeiTLKhdWuxFG100qKAguZwytjHYLkDt1/IU26Ms8wjv41MUbFd9uiKykDHyk9skdRnmiipbsEddwuojbQDyLJTBJgl7hEaQHPUEHpjHX+tTNdtptnJbzlLyNDsxFPIgi64GCoB5BOaKKqmlNXYpaOxXsbedbaaWxtXWWLJZ3eN0zxtG0gE8epxTRdJCrSRTXaakq7n4Ty+Mnn1wM4xxzRRUrdofQW3CTQBo3vXvWGJJFcAOcEgtkj0JGOn4VHcPFJClzYyG2nJIkjMjszrjqTjGMjpmiiqh7zsJ6CyNKdNt0UTxGQ/KxuMhgQQflA4HPrUdw0EdntWG1RmGMRzTAsQSAAMbfrmiiqjG6uJlyW/aHQkEDzeWcRHEcYSQ9NuOo5z2/GnXcbabYARRXVvK8UbeZHKpUk/Lt2nPy8nvRRWWidvUsovBLbWplu7G1lVtpe4ZjxuzgYHOMcnA/wqCeYWto0VveGSJgX8iKSREjU8Dgjnr3ooqoK6uRJ20EksrtLZLqfMtsQSIhctlUUHJ6AZH+c1ZKXVrZJdWouYtOnBbyVnXeATgncVOcgf40UVHNqkxlKxtrq6TOkpMkRGXRrjlz3bgAfxY5z9OtV9QeJZTDBBPDcZMe43J+ZuNxPXv3z+FFFUne/kD6E/lSGyW6it7WMIyostuWDK3HODjPIPc96hhea9lPlCSUKwJZY443ZwSSSc9B6UUUp+6tAWrP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lie on a bed or the floor. Bend the \"good\" knee and&nbsp;place the foot on the floor. Keep the injured leg straight. On the injured side, tighten the quadriceps, keep the&nbsp;knee straight, and lift the leg about 18 inches (45 cm)&nbsp;off the floor. Slowly lower the leg back to the bed or floor. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12432=[""].join("\n");
var outline_f12_9_12432=null;
var title_f12_9_12433="Fungal infection";
var content_f12_9_12433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peristomal fungal infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fungal infection presents as a maculopapular rash with distinct satellite lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12433=[""].join("\n");
var outline_f12_9_12433=null;
var title_f12_9_12434="Screening for esophageal varices";
var content_f12_9_12434=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Screening for esophageal varices (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/9/12434/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12434/contributors\" id=\"au5574\">",
"       Bruce A Runyon, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/9/12434/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12434/contributors\" id=\"se4632\">",
"       Lawrence S Friedman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/9/12434/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12434/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?12/9/12434?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ESOPHAGEAL VARICES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Cirrhosis is a disease in which the liver becomes severely scarred, usually as a result of many years of continuous injury. The most common causes of cirrhosis include alcohol abuse, chronic hepatitis B or C, and fatty liver due to obesity.",
"    </p>",
"    <p>",
"     Varices are expanded blood vessels in the esophagus, the tube that connects the mouth and stomach. Esophageal varices are a common complication of advanced cirrhosis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      \"Patient information: Cirrhosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT ARE ESOPHAGEAL VARICES?",
"     </span>",
"    </p>",
"    <p>",
"     Varices are expanded blood vessels that develop most commonly in the esophagus and stomach (",
"     <a class=\"graphic graphic_figure graphicRef63611 \" href=\"UTD.htm?8/39/8819\">",
"      figure 1",
"     </a>",
"     ). In people with cirrhosis, varices develop when blood flow through the liver is obstructed (blocked) by scarring, increasing the pressure inside the portal vein, which carries blood from the intestines to the liver; this condition is called portal hypertension.",
"    </p>",
"    <p>",
"     Portal hypertension leads to an increase in the blood pressure inside the veins in the lower esophagus and stomach. These veins were not designed for the higher pressure, and thus they begin to expand, resulting in varices. Once varices develop, they can remain stable, increase in size (if the liver disease worsens), or decrease in size (if the liver disease improves).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      COMPLICATIONS OF ESOPHAGEAL VARICES",
"     </span>",
"    </p>",
"    <p>",
"     Esophageal varices are a potentially serious complication of cirrhosis. Without treatment, between 25 and 40 percent of people with varices will experience an episode of severe bleeding (hemorrhage), which can cause significant illness or even death. Approximately 15 percent of people who bleed from varices will die, emphasizing the importance of preventing bleeding and treating the liver disease.",
"    </p>",
"    <p>",
"     Varices do not cause symptoms until they leak or rupture, leading to massive bleeding. Signs of bleeding from varices can include vomiting blood, dark-colored or black stools, and lightheadedness. If bleeding is severe, the person may lose consciousness.",
"    </p>",
"    <p>",
"     Bleeding varices require emergency medical treatment. If not treated quickly, a large amount of blood can be lost and there is a significant risk of dying. If one or more of these symptoms develop, the person needs to seek emergency care, available in the United States by calling 911. Patients who are bleeding should not try to drive to the hospital or have someone else drive them. They should call 911.",
"    </p>",
"    <p>",
"     Experts recommend that all people with cirrhosis have a screening test to determine if varices are present. If varices are discovered, one or more treatments may be recommended to prevent bleeding.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HOW ARE ESOPHAGEAL VARICES DETECTED?",
"     </span>",
"    </p>",
"    <p>",
"     Because of the serious consequences of bleeding, and because treatment can reduce this risk, experts recommend that all people with cirrhosis undergo testing to determine if varices are present.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Upper endoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common way to detect varices is with a procedure known as upper endoscopy. During this procedure, the person is sedated, and a clinician inserts a thin, lighted, flexible tube with a camera through the person's mouth to view the lining of the esophagus and upper stomach. This procedure is described in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If no varices are detected, experts usually recommend repeating the upper endoscopy in three years. If varices are detected, endoscopy is usually repeated every two to three years to monitor for enlargement of the varices. If a medication is given to reduce the risk of bleeding (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Beta blockers'",
"     </a>",
"     below), the endoscopy does not usually need to be repeated. The timing of repeat endoscopy depends upon the appearance of the varices, the cause of the liver disease, and the person's overall health.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Capsule endoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A less commonly used alternative to upper endoscopy involves swallowing a capsule that contains a tiny camera. The patient swallows the capsule while lying on the right side, and then drinks sips of water every 30 seconds. The capsule transmits photographs of the lining of the esophagus and stomach to a recording device worn outside the body. A clinician then reviews the photographs to determine if there are any abnormalities. Capsule endoscopy is more expensive than traditional endoscopy, and it is not available at all centers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Determining the risk of bleeding from esophageal varices",
"     </span>",
"     &nbsp;&mdash;&nbsp;A person's risk of bleeding from varices depends upon a number of factors, including the size, shape, location, and appearance of the varices, as well as the severity of the person's liver disease and previous history of bleeding from varices. A treatment to reduce the risk of bleeding is recommended in selected patients with esophageal varices. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"      \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TREATMENTS TO PREVENT BLEEDING FROM ESOPHAGEAL VARICES",
"     </span>",
"    </p>",
"    <p>",
"     If varices are detected, one or more treatments are usually recommended to reduce the risk of bleeding. The risk of the treatment must be weighed against the benefit for each patient. For example, beta blockers may decrease survival in patients who have refractory ascites (fluid in the abdomen that does not respond to standard treatment). Beta blockers may also make ascites more difficult to treat. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"      \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Avoid alcohol",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the most important ways to reduce the risk of bleeding from varices is to stop drinking alcohol. Alcohol can worsen cirrhosis, increase the risk of bleeding, and significantly increase the risk of dying. It can be extremely difficult to stop drinking alcohol, especially for people who have been drinking heavily for many years. Talk to a healthcare provider about treatment and support programs for alcoholism.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with cirrhosis have fatty liver disease due to obesity. Obesity may be the sole cause of liver damage, or may be a contributing factor. Losing weight can remove fat from the liver and may reduce further injury. Treatments to assist with weight loss are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"      \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Beta blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beta blockers, which are traditionally used to treat high blood pressure, are the most commonly recommended medication to prevent bleeding from varices. Beta blockers decrease pressure inside of the varices, which can reduce the risk of bleeding by 45 to 50 percent [",
"     <a class=\"abstract\" href=\"UTD.htm?12/9/12434/abstract/1\">",
"      1",
"     </a>",
"     ]. There are several forms of beta blockers. The two most commonly used beta blockers for prevention of bleeding are propranolol (Inderal&reg;) and nadolol (Corgard&reg;). The dose of the medication is usually adjusted based upon the person's blood pressure and heart rate. It is important to take the medication every day exactly as directed.",
"    </p>",
"    <p>",
"     Importantly, other types of beta blockers (eg, labetalol, atenolol, metoprolol) may not be effective in reducing the risk of bleeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H421071986\">",
"     <span class=\"h3\">",
"      Side effects of beta blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of beta blockers are fatigue and dizziness. They can also cause insomnia, a decreased ability to exercise, a slow heart rate, impotence, and cold hands and feet. The beta blockers used for cirrhosis can worsen symptoms of asthma, other lung diseases, or blood vessel disease (such as peripheral vascular disease). As a result, they normally are not prescribed for people with these conditions. Side effects should be discussed with a healthcare provider before stopping the medication.",
"    </p>",
"    <p>",
"     As noted above, beta blockers may decrease survival in patients who have refractory ascites (fluid in the abdomen that does not respond to standard treatment). Beta blockers may also make ascites more difficult to treat. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"      \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Variceal band ligation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Variceal band ligation is a procedure that is done during endoscopy. A physician places small rubber bands around varices to prevent them from bleeding. Endoscopy is usually repeated every one to two weeks after the bands are placed to determine if additional bands are needed. Medications to reduce stomach acid, known as proton pump inhibitors (eg, omeprazole, lansoprazole, pantoprazole, esomeprazole, dexlansoprazole) are taken twice daily after banding to help speed healing of the",
"     <span class=\"nowrap\">",
"      erosions/ulcers",
"     </span>",
"     that develop when the band falls off of the shrinking varix.",
"    </p>",
"    <p>",
"     Variceal band ligation is usually performed in people who have bled from varices. However, it can also be performed to prevent bleeding, especially in people whose varices are large",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     have other features that increase the risk of bleeding. It may also be performed in people who cannot tolerate beta blockers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287277256\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29457048\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/40/8834?source=see_link\">",
"      Patient information: Esophageal varices (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29457063\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44084?source=see_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"      Endoscopic variceal ligation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39511?source=see_link\">",
"      Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000268.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000268.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/bleeding/\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/bleeding/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Liver Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.liverfoundation.org/\">",
"      www.liverfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Information about alcoholism from the National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/alcoholism.html\">",
"      www.nlm.nih.gov/medlineplus/alcoholism.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?12/9/12434/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?12/9/12434?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12434/abstract/1\">",
"      Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. Final report of a multicenter randomized trial. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. J Hepatol 1989; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12434/abstract/2\">",
"      Burroughs AK. The natural history of varices. J Hepatol 1993; 17 Suppl 2:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12434/abstract/3\">",
"      Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12434/abstract/4\">",
"      Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001; 345:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12434/abstract/5\">",
"      Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12434/abstract/6\">",
"      Serst&eacute; T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52:1017.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f12_9_12434=[""].join("\n");
var outline_f12_9_12434=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ESOPHAGEAL VARICES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT ARE ESOPHAGEAL VARICES?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           COMPLICATIONS OF ESOPHAGEAL VARICES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HOW ARE ESOPHAGEAL VARICES DETECTED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TREATMENTS TO PREVENT BLEEDING FROM ESOPHAGEAL VARICES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/39/8819\" title=\"figure 1\">",
"           Esophageal varices PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f12_9_12435="Pegademase bovine: Drug information";
var content_f12_9_12435=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegademase bovine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F206681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose should be individualized based on monitoring of plasma ADA activity levels and dATP content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adenosine deaminase deficiency (enzyme replacement therapy):",
"     </b>",
"     I.M.: Infants and Children: Dose given every 7 days, 10 units/kg the first dose, 15 units/kg the second dose, and 20 units/kg the third dose; maintenance dose: 20 units/kg/week is recommended depending on patient's ADA level; maximum single dose: 30 units/kg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adagen&reg;: 250 units/mL (1.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6781716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer intramuscularly; do not dilute or mix with other medications prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enzyme replacement therapy for adenosine deaminase (ADA) deficiency in patients with severe combined immunodeficiency disease (SCID) who are not candidates for or who have failed bone marrow transplant",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1%: Headache, pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Autoimmune hemolytic anemia, erythema (injection site), hemolytic anemia, thrombocythemia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not to be used as preparatory or support therapy for bone marrow transplantation; severe thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody formation: Development of antibodies has been reported in patients resulting in more rapid clearance of pegademase bovine. In patients who experience a persistent decrease in preinjection levels of plasma ADA to &lt;10 micromole/hour/mL and have had other causes ruled out (eg, improper storage of vials, improper handling of plasma sample), antibody formation should be considered and a specific assay for antibody ADA should be performed. Dosage adjustments may be required in patients developing antibodies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune status: Failure to maintain adequate levels of plasma ADA activity will increase patients risk for infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia; should not be used in patients with severe thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not a substitute for bone marrow transplant; should be used in conjunction with continued close monitoring and appropriate diagnostic tests and therapy. Therapy is not a cure for SCID and must be continued.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Pegademase Bovine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentostatin: Pegademase Bovine may diminish the therapeutic effect of Pentostatin. Pentostatin may diminish the therapeutic effect of Pegademase Bovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6781710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. The benefits versus risks should be considered carefully before initiating pegademase bovine therapy in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6781712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adagen Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 units/mL (1.5 mL): $4684.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6781718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Plasma ADA activity prior to treatment, then a preinjection level every 1-2 weeks for the first 8-12 weeks, then twice a month for the next 3-9 months, then monthly until after 18-24 months. After 24 months monitor level every 2-4 months. If therapy is interrupted, more frequent monitoring is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monitor red cell dATP prior to treatment and until levels have decreased adequately (usually after 2 months of maintenance therapy), then monitor 2-4 times a year for first year and 2-3 times a year thereafter. If therapy is interrupted, more frequent monitoring is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monitor immune function and clinical status.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6781715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Plasma ADA activity: Recommended maintenance trough level: 15-35 micromole/hour/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red cell dATP: After 2 months of maintenance therapy, levels should decrease to &le;0.005-0.015 micromole/mL (normal dATP value: &lt;0.001 micromole/mL) or &le;1% of total erythrocyte adenine nucleotide (ATP + dATP) content with a normal ATP level",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adagen (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adenosine deaminase is an enzyme that catalyzes the deamination of both adenosine and deoxyadenosine. Hereditary lack of adenosine deaminase activity results in severe combined immunodeficiency disease, a fatal disorder of infancy characterized by profound defects of both cellular and humoral immunity. It is estimated that 25% of patients with the autosomal recessive form of severe combined immunodeficiency lack adenosine deaminase. Pegademase bovine is a (modified) enzyme replacement for adenosine deaminase deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Plasma ADA half-life (following administration): Range: 3 to &gt;6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Plasma adenosine deaminase activity: 2-3 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9744 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12435=[""].join("\n");
var outline_f12_9_12435=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206676\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206677\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206684\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206681\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206665\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206652\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6781716\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206666\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206683\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206669\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206656\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299827\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206660\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206662\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6781710\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6781712\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323628\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6781718\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6781715\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206670\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206655\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206668\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9744|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_9_12436="Pyrethrins: Drug information";
var content_f12_9_12436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrethrins: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/20/326?source=see_link\">",
"    see \"Pyrethrins: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-200&reg; Lice Treatment Kit [OTC];",
"     </li>",
"     <li>",
"      A-200&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Licide&reg; [OTC];",
"     </li>",
"     <li>",
"      Pronto&reg; Complete Lice Removal System [OTC];",
"     </li>",
"     <li>",
"      Pronto&reg; Plus Lice Killing Mousse Plus Vitamin E [OTC];",
"     </li>",
"     <li>",
"      Pronto&reg; Plus Lice Killing Mousse Shampoo Plus Natural Extracts and Oils [OTC];",
"     </li>",
"     <li>",
"      Pronto&reg; Plus Warm Oil Treatment and Conditioner [OTC];",
"     </li>",
"     <li>",
"      RID&reg; Maximum Strength [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pronto&reg; Lice Control;",
"     </li>",
"     <li>",
"      R &amp; C&trade; II;",
"     </li>",
"     <li>",
"      R &amp; C&trade; Shampoo/Conditioner;",
"     </li>",
"     <li>",
"      RID&reg; Mousse",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiparasitic Agent, Topical;",
"     </li>",
"     <li>",
"      Pediculocide;",
"     </li>",
"     <li>",
"      Shampoo, Pediculocide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of",
"      <i>",
"       Pediculus humanus",
"      </i>",
"      infestations:",
"     </b>",
"     <i>",
"      Topical products:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Apply enough solution to completely wet infested area, including hair",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Allow to remain on area for 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wash and rinse with large amounts of warm water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Use fine-toothed comb to remove lice and eggs from hair",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo hair to restore body and luster",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment may be repeated if necessary once in a 24-hour period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Repeat treatment in 7-10 days to kill newly hatched lice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Keep out of eyes when rinsing hair; protect eyes with a wash cloth or towel",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Head lice, body lice:",
"     </b>",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kit:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-200&reg; Lice Treatment Kit:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Shampoo: Pyrethrins 0.33% and piperonyl butoxide 4% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution [spray; for bedding; not for human or animal use]: Permethrin 0.5% (180 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     [packaged with nit removal comb]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pronto&reg; Complete Lice Removal System:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Shampoo: Pyrethrins 0.33% and piperonyl butoxide 4% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution, topical: Benzalkonium chloride 0.1% (60 mL) [lice egg remover antiseptic]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     [packaged with household furniture spray and nit removal comb]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pronto&reg; Plus Warm Oil Treatment and Conditioner: Pyrethrins 0.33% and piperonyl butoxide 4% (36 mL) [fruity herbal scent; packaged with nit removal comb]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-200&reg; Maximum Strength: Pyrethrins 0.33% and piperonyl butoxide 4% (60 mL, 120 mL) [contains benzyl alcohol; packaged with nit removal comb]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Licide&reg;: Pyrethrins 0.33% and piperonyl butoxide 4% (120 mL) [packaged with nit removal comb; also available in a kit containing shampoo, household spray, and nit removal comb]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pronto&reg; Plus Lice Killing Mousse Shampoo Plus Natural Extracts and Oils: Pyrethrins 0.33% and piperonyl butoxide 4% (60 mL) [packaged with nit removal comb]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pronto&reg; Plus Lice Killing Mousse Shampoo Plus Vitamin E: Pyrethrins 0.33% and piperonyl butoxide 4% (120 mL) [blue mousse shampoo; contains vitamin E; packaged with nit removal comb]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RID&reg; Maximum Strength: Pyrethrins 0.33% and piperonyl butoxide 4% (60 mL, 120 mL, 180 mL, 240 mL) [packaged with nit removal comb; also available in a kit containing shampoo, gel, and furniture spray]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F215836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid touching eyes, mouth, or other mucous membranes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of",
"     <i>",
"      Pediculus humanus",
"     </i>",
"     infestations (head lice, body lice, pubic lice, and their eggs)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, stinging, irritation with repeat use",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrethrins, ragweed, chrysanthemums, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; do not use near the eye, in eyelashes or eyebrows. Avoid contact with mucosal tissues (nasal, oral, or genital).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14277140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnant women may be treated with pyrethrins and piperonyl butoxide (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14277141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lactating women may be treated with pyrethrins and piperonyl butoxide (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Pronto)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (150 mL): $4.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Pronto External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.33-4% (1): $6.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Tegrin-LT Lice Treatment Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.33-3.15% (1): $9.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Licide Maximum Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.33-4% (59 mL): $4.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (RID External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.33-4% (118 mL): $10.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Licide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.33-4% (120 mL): $5.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Pronto External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.33-4% (120 mL): $9.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Tegrin-LT Lice Treatment External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.33-3.15% (60 mL): $6.05",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F215841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kwell-P (TR);",
"     </li>",
"     <li>",
"      Lice-Enz (GR);",
"     </li>",
"     <li>",
"      Milice (IT);",
"     </li>",
"     <li>",
"      Spray-Pax (FR, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyrethrins are derived from flowers that belong to the chrysanthemum family. The mechanism of action on the neuronal membranes of lice is similar to that of DDT. Piperonyl butoxide is usually added to pyrethrin to enhance the product's activity by decreasing the metabolism of pyrethrins in arthropods.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via ester hydrolysis and hydroxylation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12436/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coats JR, &ldquo;Mechanisms of Toxic Action and Structure-Activity Relationships for Organochlorine and Synthetic Pyrethroids Insecticide,&rdquo;",
"      <i>",
"       Environ Health Perspect",
"      </i>",
"      , 1990, 87:255-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12436/abstract-text/2176589/pubmed\" id=\"2176589\" target=\"_blank\">",
"        2176589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Culver CA, Malina JJ, and Talbert RL, &ldquo;Probable Anaphylactoid Reaction to a Pyrethrin Pediculicide Shampoo,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(11):846-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12436/abstract-text/3197386/pubmed\" id=\"3197386\" target=\"_blank\">",
"        3197386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorman DC and Beasley VR, &ldquo;Neurotoxicity of Pyrethrin and the Pyrethroid Insecticides,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1991, 33(3):238-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12436/abstract-text/1713367/pubmed\" id=\"1713367\" target=\"_blank\">",
"        1713367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1017):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12436/abstract-text/9442765/pubmed\" id=\"9442765\" target=\"_blank\">",
"        9442765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12436/abstract-text/8602186/pubmed\" id=\"8602186\" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wax PM and Hoffman RS, &ldquo;Fatality Associated With Inhalation of a Pyrethrin Shampoo,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1994, 32(4):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12436/abstract-text/8057406/pubmed\" id=\"8057406\" target=\"_blank\">",
"        8057406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9837 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12436=[""].join("\n");
var outline_f12_9_12436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215847\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215848\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215858\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215849\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215855\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215850\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215834\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215821\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215836\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215835\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215856\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215839\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215825\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299966\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215829\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215831\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14277140\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14277141\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323766\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215841\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215824\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215838\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/20/326?source=related_link\">",
"      Pyrethrins: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_9_12437="Possible pathologic cascade ALS and FTLD-linked molecules";
var content_f12_9_12437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Possible pathologic cascade of amyotrophic lateral sclerosis (ALS)/frontotemporal lobar degeneration (FTLD)-linked molecules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    TAR DNA-binding protein (TDP-43) and fused in sarcoma (FUS) induce a conjoint pathologic cascade of neurodegeneration that leads to ALS/FTLD with ubiquitin-positive inclusions. Ataxin-2 possibly promotes this cascade. Recent pathologic and biochemical evidence indicates that valosin containing protein (VCP) and progranulin (PGRN) may be located upstream of TDP-43 in the pathologic cascade. Cu/Zn SOD1 may contribute to an independent pathologic process or join the pathologic cascade downstream of TDP-43/FUS. The role of optineurin in the pathologic cascade remains to be elucidated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ito D, Suzuki N. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 2011; 77:1636. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12437=[""].join("\n");
var outline_f12_9_12437=null;
var title_f12_9_12438="Cefepime: Pediatric drug information";
var content_f12_9_12438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefepime: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"    see \"Cefepime: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/22/39267?source=see_link\">",
"    see \"Cefepime: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14482579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Seizure Risk with Cefepime",
"     </span>",
"     <span class=\"collapsible-date\">",
"      June 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA is reminding health care providers about the need to adjust the dosage of cefepime in patients with renal impairment. Cases of nonconvulsive status epilepticus have been associated with the use of cefepime, primarily in patients with renal impairment who did not receive appropriate dosage adjustments; however, some of the cases occurred in patients who appropriately received dosage adjustment according to their degree of renal impairment.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       To minimize the risk of seizures, healthcare providers should adjust the dosage of cefepime in patients with creatinine clearance &le;60 mL/minute. If seizure associated with cefepime therapy does occur, consider discontinuing cefepime or making appropriate adjustment in dosage, as necessary, based on renal function. The label is being revised to highlight this risk.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm309661.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm309661.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F147316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Maxipime&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Fourth Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PNA &lt;14 days: 30 mg/kg/dose every 12 hours (Capparelli, 2005); consider increasing to 50 mg/kg/dose every 12 hours for pseudomonal infections (Lima-Rogel, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PNA &ge;14 days: 50 mg/kg/dose every 12 hours (Lima-Rogel, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"      see \"Cefepime: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants 1 month to Adolescents 16 years and &le;40 kg: 50 mg/kg/dose (maximum dose: 2 g) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Febrile neutropenic patients: 50 mg/kg/dose (maximum dose: 2 g) every 8 hours for 7 days or until neutropenia resolves",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cefepime has been studied in 12 cystic fibrosis patients (ages 4-41 years) with bronchopulmonary infection at a dose of 50 mg/kg/dose every 8 hours (maximum dose: 2 g/dose every 8 hours); cefepime was as effective as cefotaxime in 90 children &lt;15 years of age who were randomized to receive cefepime 50 mg/kg/dose every 8 hours (n=43) or cefotaxime 50 mg/kg/dose every 6 hours (n=47) for the treatment of bacterial meningitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 1-2 g every 12 hours; high doses or more frequent administration may be required in pseudomonal infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     UTIs: 0.5-2 g every 12 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Empiric monotherapy in febrile neutropenia: 2 g every 8 hours for 7 days or until neutropenia resolves",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intra-abdominal infection, complicated: 2 g every 12 hours with metronidazole for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: Recommended maintenance schedule based on creatinine clearance (mL/minute), compared to normal dosing schedule: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Cefepime Hydrochloride",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL/minute)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Recommended Maintenance Schedule",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;60",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (normal recommended dosing schedule)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 8 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 12 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11-29",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 g every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 mg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 g every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Removed to a lesser extent than hemodialysis; administer normal recommended dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Initial: 1 g (single dose) on day 1. Maintenance: 500 mg once daily (1 g once daily in febrile neutropenic patients)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as hydrochloride: 1 g (50 mL); 2 g (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride: 500 mg, 1 g, 2 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Cefepime may be administered by I.V. intermittent infusion over 20-30 minutes; final concentration for I.V. administration should not exceed 40 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     LR; in adult clinical trials, cefepime has been administered by direct I.V. injection over 3-5 minutes at final concentrations of 40 mg/mL (Garrelts, 1999) and 100 mg/mL (Jaruratanasirikul, 2002; Lipman, 1999) for severe infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Deep I.M. injection. May dilute vial using SWI, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or 0.5% or 1% lidocaine to a final concentration of 280 mg/mL (see package insert)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS, bacteriostatic water, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, ampicillin/sulbactam, anidulafungin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cyclophosphamide, cytarabine, dactinomycin, dexamethasone sodium phosphate, dexmedetomidine, docetaxel, doxorubicin liposome, fenoldopam, fluconazole, fludarabine, fluorouracil, furosemide, gentamicin, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, insulin (regular), ketamine, leucovorin calcium, lorazepam, melphalan, mesna, methotrexate, methylprednisolone sodium succinate, metronidazole, milrinone, mycophenolate, paclitaxel, piperacillin/tazobactam, ranitidine, remifentanil, sargramostim, sodium bicarbonate, sufentanil, sulfamethoxazole/trimethoprim, telavancin, thiotepa, ticarcillin/clavulanate, tigecycline, tobramycin, valproate sodium, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acetylcysteine, acyclovir, amphotericin B, amphotericin B cholesteryl sulfate complex, caspofungin, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, dacarbazine, daunorubicin, diazepam, diphenhydramine, doxorubicin, droperidol, enalaprilat, erythromycin lactobionate, etoposide, etoposide phosphate, famotidine, filgrastim, floxuridine, gallium nitrate, ganciclovir, haloperidol, hydroxyzine, idarubicin, ifosfamide, magnesium sulfate, mannitol, mechlorethamine, meperidine, metoclopramide, midazolam, mitomycin, mitoxantrone, morphine, nalbuphine, nicardipine, ondansetron, phenytoin, prochlorperazine edisylate, promethazine, streptozocin, theophylline, vinblastine, vincristine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dobutamine, dopamine, morphine, propofol, vancomycin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vial at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F); protect from light; incompatible with metronidazole, vancomycin, aminoglycosides, and aminophylline. Cefepime diluted with NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, and D",
"     <sub>",
"      5",
"     </sub>",
"     NS is stable for 24 hours at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) or for 7 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pneumonia, uncomplicated skin and soft tissue infections, urinary tract infections (including pyelonephritis), and as empiric therapy for febrile neutropenic patients (FDA approved in ages 2 months to 16 years and adults); used in combination with metronidazole for complicated intra-abdominal infections (FDA approved in adults). Cefepime is a fourth generation cephalosporin with activity against gram-negative bacteria, including",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     ,",
"     <i>",
"      M morganii",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     , and strains of Acinetobacter, Citrobacter, Enterobacter, Klebsiella, Providencia, and Serratia; active against gram-positive bacteria, such as",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     , and",
"     <i>",
"      S. pneumoniae",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9645319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cefepime may be confused with cefixime, cefTAZidime",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F147358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Positive Coombs' test without hemolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, PT abnormal, PTT abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local:Inflammation, pain, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, alkaline phosphatase increased, anaphylactic shock, anaphylaxis, bilirubin increased, BUN increased, colitis, coma, confusion, creatinine increased, encephalopathy, hallucinations, hematocrit decreased, hypercalcemia, hyperkalemia, hyperphosphatemia, hypocalcemia, leucopenia, myoclonus, neutropenia, nonconvulsive status epilepticus, oral moniliasis, pseudomembranous colitis, seizure, stupor, thrombocytopenia, urticaria, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Aplastic anemia, erythema multiforme, hemolytic anemia, hemorrhage, pancytopenia, PT prolonged, renal dysfunction, Stevens-Johnson syndrome, superinfection, toxic epidermal necrolysis, toxic nephropathy, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefepime, any component, or other cephalosporins, penicillins, or beta-lactam antibiotics",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5562223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer does not recommend the use of cefepime in pediatric patients for the treatment of serious infections due to",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b, for suspected meningitis, or for meningeal seeding from a distant infection site. However, limited data suggest that cefepime may be a valuable alternative for treating bacterial meningitis in children in conjunction with other agents like vancomycin in areas with cephalosporin nonsusceptible pneumococci. Use with caution in patients with a history of GI disease or seizures. May be associated with increased INR, especially in patients who are nutritionally-deficient, have prolonged treatment, or who have hepatic or renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Modify dosage in patients with severe renal impairment;",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea has been reported with the use of cefepime; prolonged use may result in superinfection; use with caution in patients with penicillin hypersensitivity; do not use in patients with immediate-type hypersensitivity reactions to penicillin. CNS adverse events, including encephalopathy, confusion, hallucinations, stupor, coma, myoclonus, and seizures, have been reported, most commonly in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (4th Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5947925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Cefepime crosses the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor renal and hepatic function periodically; number and type of stools/day for diarrhea; CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates (PMA &lt;30 weeks): 0.51 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2 months to 6 years: 0.32-0.35 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 16-20 L; penetrates into inflammatory fluid at concentrations &sim;80% of serum concentrations and into bronchial mucosa at concentrations &sim;60% of plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Very little",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2 months to 6 years: 1.77-1.96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: At least 85% eliminated as unchanged drug in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 45% to 68% removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/22/39267?source=see_link\">",
"      see \"Cefepime: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report side effects such as diarrhea, dyspepsia, headache, blurred vision, and lightheadedness to your physician",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arguedas AG, Stutman HR, Zaleska M, et al, &ldquo;Cefepime. Pharmacokinetics and Clinical Response in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1992, 146(7):797-802.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/1496945/pubmed\" id=\"1496945\" target=\"_blank\">",
"        1496945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Reed MD, Lemon E, et al, &ldquo;Pharmacokinetics (PK) of Cefepime in Pediatric Patients Administered Single and Multiple 50 mg/kg Doses Every 8 Hours by the Intravenous (I.V.) or Intramuscular (I.M.) Route,&rdquo; 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994, Orlando, Fl. Abs. A69.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capparelli E, Hochwald C, Rasmussen M, et al, \"Population Pharmacokinetics of Cefepime in the Neonate,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005, 49(7):2760-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/15980347/pubmed\" id=\"15980347\" target=\"_blank\">",
"        15980347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garrelts JC and Wagner DJ, \"The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(12):1258-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/10630824/pubmed\" id=\"10630824\" target=\"_blank\">",
"        10630824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haase MR, \"Acute Bacterial Meningitis in Children,\"",
"      <i>",
"       J Pharm Pract",
"      </i>",
"      , 2004, 17:392.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaruratanasirikul S, Sriwiriyajan S, and Ingviya N, \"Continuous Infusion Versus Intermittent Administration of Cefepime in Patients With Gram-Negative Bacilli Bacteraemia,\"",
"      <i>",
"       J Pharm Pharmacol",
"      </i>",
"      , 2002, 54(12):1693-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/12542901/pubmed\" id=\"12542901\" target=\"_blank\">",
"        12542901",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lima-Rogel V, Medina-Rojas EL, Del Carmen Mil&aacute;n-Segovia R, et al, \"Population Pharmacokinetics of Cefepime in Neonates With Severe Nosocomial Infections,\"",
"      <i>",
"       J Clin Pharm Ther",
"      </i>",
"      , 2008, 33(3):295-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/18452417/pubmed\" id=\"18452417\" target=\"_blank\">",
"        18452417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipman J, Wallis SC, and Rickard C, \"Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs With Revised Dosing,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1999, 43(10):2559-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/10508045/pubmed\" id=\"10508045\" target=\"_blank\">",
"        10508045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saez-Llorens X, Castano E, Garcia R, et al, &ldquo;Prospective Randomized Comparison of Cefepime and Cefotaxime for Treatment of Bacterial Meningitis in Infants and Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1995, 39(4):937-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/7785999/pubmed\" id=\"7785999\" target=\"_blank\">",
"        7785999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynd MA and Paladino JA, &ldquo;Cefepime: A Fourth-Generation Parenteral Cephalosporin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(12):1414-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/9/12438/abstract-text/8968455/pubmed\" id=\"8968455\" target=\"_blank\">",
"        8968455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13126 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-658DE962AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12438=[""].join("\n");
var outline_f12_9_12438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14482579\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147316\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045931\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442203\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045922\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147294\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045934\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147359\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045926\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045933\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645319\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147358\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045937\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5562223\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045921\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298988\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147290\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5947925\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045930\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045920\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045936\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045928\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13126|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=related_link\">",
"      Cefepime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/22/39267?source=related_link\">",
"      Cefepime: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_9_12439="MRI Transverse myelitis and MS";
var content_f12_9_12439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    37 year old man with multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted sagittal (A) and axial (B) images show a focus of hyperintensity in the posterior columns of the cervical spinal cord at the C2 level. Post-gadolinium T1-weighted sagittal (C) and axial (D) images demonstrate enhancement consistent with an active plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12439=[""].join("\n");
var outline_f12_9_12439=null;
var title_f12_9_12440="Surgical therapy of osteoarthritis";
var content_f12_9_12440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical therapy of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/9/12440/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12440/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/9/12440/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12440/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/9/12440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12440/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/9/12440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of management of patients with osteoarthritis (OA) are to control pain and swelling, to minimize disability, to improve the quality of life, and to help the patient develop his or her role in the management team. Management should be individualized to the patient&rsquo;s expectations, to the levels of function and activity, to the joints involved, to the severity of the patient&rsquo;s disease, to occupational and vocational needs, and to the nature of any coexisting medical problems.",
"   </p>",
"   <p>",
"    Surgical interventions for patients with OA are generally reserved for those who have failed less invasive modes of therapy. This topic will review the effectiveness of surgical approaches used to treat OA. Pharmacologic and nonpharmacologic approaches to the treatment of OA other than surgery are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARTHROSCOPIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical interventions that utilize arthroscopic techniques for the treatment of osteoarthritis are controversial. Arthroscopic debridement with lavage and arthroscopic synovectomy are two procedures that have been employed in selected patients with OA of the knee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Joint irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint irrigation is an integral part of all arthroscopies. It is necessary to distend the joint for adequate visualization and to remove blood and debris that would otherwise cloud the view [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that joint irrigation relieves pain in knee OA by removing cartilaginous debris with a resultant decreased burden on synovium. The data supporting this hypothesis include the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The demonstration of cartilage fragments in synovial fluid and in the synovium of osteoarthritic knees [",
"      <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The induction of experimental osteoarthritis in dogs and rabbits by intraarticular injection of autologous cartilage [",
"      <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The in vitro demonstration of protease release from cultured monocytes challenged with cartilage fragments [",
"      <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Joint lavage may be performed with or without arthroscopic guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Arthroscopic joint irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct, three-armed comparison of arthroscopically directed lavage, arthroscopically directed lavage and debridement, and sham surgery was performed in a study that randomized 180 patients with radiographic and symptomatic osteoarthritis of the knee to one of the three procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients were followed for 24 months; the result of this blinded study was that there was no clinically important or statistically significant advantage in the reduction of knee pain or in the improvement of knee function in the groups that received an arthroscopic intervention (lavage alone or lavage and debridement) when compared with the sham group. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Arthroscopic debridement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another trial randomly assigned 32 patients with non-endstage knee OA to arthroscopic surgery or to tidal knee irrigation in osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients randomized to arthroscopy underwent this procedure in an operating room with a standard 4 mm arthroscope and with general anesthesia. All patients received continuous saline irrigation during the arthroscopic procedure and had the following interventions performed under arthroscopic guidance as indicated by findings noted at arthroscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Debridement of torn menisci and removal of meniscal and cruciate ligament fragments",
"     </li>",
"     <li>",
"      Removal of proliferative synovium",
"     </li>",
"     <li>",
"      Excision of loose articular cartilage fragments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients randomized to the tidal knee irrigation group received closed-needle lavage as performed in a previous study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/1\">",
"     1",
"    </a>",
"    ]. Both groups received non-narcotic analgesia and physical therapy.",
"   </p>",
"   <p>",
"    Measurements of outcome were made over a 12-month period of follow-up and included a variety of clinical parameters that were assessed by clinician assessors blinded to treatment group. These included pain and functional status measures, the Arthritis Impact Measurement Scales (AIMS), global measures of well-being by visual analog scales, costs of clinician and therapist visits, employment status, and the use of aides to help with activities of daily living.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant improvements in pain, tenderness, physical activity, and global assessment of disease activity were noted in the arthroscopy group at three months; pain, tenderness and physical activity changes were sustained at 12 months. Significant reductions in pain were noted for those in the tidal knee irrigation group at 3 and 12 months.",
"     </li>",
"     <li>",
"      At three months of follow-up, there were no significant differences between the two treatment groups for pain, functional status, or patient and clinician global assessments of disease activity",
"     </li>",
"     <li>",
"      At 12 months, there were no differences in medication costs, utilization of medical services, or indirect costs related to employment or to use of household help.",
"     </li>",
"     <li>",
"      Significant improvements in knee tenderness and clinician&rsquo;s global assessment scores at 12 months were more common with tidal knee irrigation (58 percent versus 29 percent with arthroscopy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that arthroscopically guided removal of soft tissue abnormalities did not generally lead to reductions in pain and knee dysfunction associated with non-endstage knee osteoarthritis beyond those which could be achieved with closed-joint irrigation. Thus, most patients with non-endstage knee osteoarthritis could be treated with nonsurgical modalities.",
"   </p>",
"   <p>",
"    The major flaw in this study is that the two groups were controlled for radiographic abnormalities but not for intraarticular pathology; the articular cartilage damage was only noted in patients who underwent arthroscopic procedures. A significant difference in irreversible damage may have adversely affected outcomes since patients with severe disease noted arthroscopically may not have been able to respond to a particular therapeutic intervention. Because of this limitation, it is difficult to conclude that arthroscopic irrigation or other surgical procedures are no better than nonvisualized irrigation in patients with knee OA.",
"   </p>",
"   <p>",
"    Nonvisualized tidal irrigation ensures irrigation only of the patellofemoral compartment and of the suprapatellar pouch. In comparison, visually guided arthroscopic irrigation ensures irrigation of all three compartments (patellofemoral, medial tibiofemoral, and lateral tibiofemoral) of the knee and enables the arthroscopist to focus on areas with extensive debris or crystalline material.",
"   </p>",
"   <p>",
"    In addition, a large, multicenter, prospective randomized study of the efficacy of irrigation by needle arthroscopy supported by the American College of Rheumatology has been completed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/9\">",
"     9",
"    </a>",
"    ]. This study used small-caliber office-based arthroscopes with local anesthesia and intravenous sedation. It compared large volume saline irrigation (3 liters) and minimal saline irrigation (less than 250 mL) in terms of clinical, functional, and cost effectiveness in patients with early knee OA who had symptoms that were unresponsive to nonsteroidal antiinflammatory drugs (NSAIDs), physical therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraarticular glucocorticoids. The follow-up period was one year. Patient self-reported pain scores were significantly lower with full irrigation than with minimal irrigation (decrease of 4.2 and 2.3, respectively).",
"   </p>",
"   <p>",
"    At one site, 70 percent of patients that entered the study had evidence of positively birefringent calcium pyrophosphate crystals at intraarticular examination; only one patient had radiographic evidence of chondrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/10\">",
"     10",
"    </a>",
"    ]. Other sites did not specifically study for the presence of these crystals. The characteristics of this crystalline material are being evaluated. However, its presence appears to predict outcome from arthroscopic irrigation; at three months after arthroscopy, significantly more patients with crystals had at least a 40 percent improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, a validated outcome instrument for patients with OA that assesses pain, stiffness, and physical function) than patients without crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/9\">",
"     9",
"    </a>",
"    ]. The best outcome as measured by the WOMAC score was seen in patients with a high concentration of crystals and with involvement of more than one compartment.",
"   </p>",
"   <p>",
"    There appears to be no beneficial interaction between joint irrigation and glucocorticoid use. This was illustrated in a prospective study that randomly assigned 98 patients with OA of the knee to receive intraarticular placebo (saline) injection, intraarticular glucocorticoids, intraarticular placebo and joint lavage, or the combination of intraarticular glucocorticoids and lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients who received either intraarticular glucocorticoids or joint lavage improved symptomatically but not functionally. Improvement from glucocorticoids was relatively short-lived, lasting only four weeks, while those who received joint irrigation had decreased knee pain lasting up to 26 weeks. Those who received glucocorticoid injections and joint irrigation were not significantly better than those who did not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that arthroscopic irrigation may be warranted in patients with inflammatory symptoms who are refractory to NSAIDs or to intraarticular glucocorticoid injections. These patients may have debris and crystalline material; irrigation may remove these particles and may lead to improved symptoms and function. However, the results of a sham surgery versus arthroscopic lavage and debridement study discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/7\">",
"     7",
"    </a>",
"    ] raise the possibility that the benefit of such procedures is due more to a powerful placebo effect of a surgical intervention than to effects on the joint per se. Office-based arthroscopic irrigation can be performed on knees and shoulders with local anesthesia and intravenous sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tidal irrigation alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2010 meta-analysis that addressed the efficacy of tidal irrigation (joint lavage) that included four randomized and",
"    <span class=\"nowrap\">",
"     placebo/sham",
"    </span>",
"    controlled trials of joint lavage concluded that, for the outcome of pain relief three months after the intervention, there was no statistically significant advantage of active lavage to",
"    <span class=\"nowrap\">",
"     placebo/sham",
"    </span>",
"    interventions (effect size [ES] -0.17, 95% CI -0.37-0.71) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/12\">",
"     12",
"    </a>",
"    ]. Assessment data from the same four studies for changes in physical function concluded that there was also no significant difference in outcomes (ES -0.15, 95% CI -0.34-0.04).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arthroscopic debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopic debridement has been widely used as a treatment for patients with symptomatic OA of the knee. As noted above, direct comparison of arthroscopic lavage, arthroscopic debridement and lavage, and sham surgery in a randomized trial in 180 predominantly white, male patients under 75 years of age found that pain and function were not significantly better in those who received an arthroscopic procedure than in those who had sham surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/7\">",
"     7",
"    </a>",
"    ]. This was the case at multiple time points from two weeks to 24 months following the intervention. The study population, predominantly men, was not representative of osteoarthritis patients in the general population, the majority of whom are women. Approximately one-quarter of the patients studied had radiographically severe osteoarthritis, a group in which little improvement from arthroscopic intervention would have been expected. Although otherwise well-designed, the lack of selection for predominantly mechanical symptoms, the large percentage of otherwise eligible patients who chose not to enroll (44 percent), and the inclusion of patients with radiographically severe osteoarthritis raise questions about the general applicability of the results of this study. In a subsequent randomized double-blind clinical trial that compared arthroscopic debridement and lavage in combination with medical and physical therapy with medical and physical therapy alone, there was no significant difference in outcomes as assessed by the WOMAC score or by the individual WOMAC pain, stiffness, or physical function subscales at the end of one year of follow-up nor at any interim time points [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/13\">",
"     13",
"    </a>",
"    ]. By including more women (63 percent) and patients with radiographically mild or moderate osteoarthritis (95 percent), this clinical trial in 178 individuals addressed some of the criticisms of the earlier, sham-controlled study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Earlier studies found that lavage with or without arthroscopy provided similar symptomatic relief and improved functional performance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/8,11,14\">",
"     8,11,14",
"    </a>",
"    ]. As an example, one study of 32 patients with osteoarthritis of the knees found similar pain relief (both in amount and in duration) among those randomized to joint lavage alone or to arthroscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/8\">",
"     8",
"    </a>",
"    ]. Compared with glucocorticoid injection, joint lavage provides a much longer duration of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Joint irrigation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some patients may not respond to lavage alone because of advanced disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concomitant soft tissue problems, such as instability and degenerative tears of the menisci, loose bodies, or malalignment. Thus, careful consideration of the patient&rsquo;s symptoms and disease extent may identify the following subset of patients who will benefit from arthroscopic lavage and debridement and in whom the additional expense is justified. Those patients with predominantly mechanical symptoms, mild to moderate roentgenographic disease, and shorter disease duration appear to do better with arthroscopy than those with severe disease, symptoms of long duration, and malalignment of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When care is taken to identify such patients by clinical history, examination, and roentgenograms, arthroscopic lavage and debridement provide a more predictable, albeit temporary, result. In one group of such patients, for example, there was an 80 percent improvement rate at one year after arthroscopic partial meniscectomy and debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/18\">",
"     18",
"    </a>",
"    ]. Likewise, patients with documented intraarticular loose bodies are candidates for arthroscopic removal of the offending material [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Arthroscopic abrasion arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopic abrasion arthroplasty, involving burring and drilling of sclerotic bone, has not been shown to be beneficial. The results are unpredictable, and the process often leads to worsening of symptoms. In one study, 50 percent of those undergoing abrasion arthroplasty required total knee replacement within three years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arthroscopic synovectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clinical trials have been performed that study the efficacy of arthroscopic synovectomy in patients with OA. It is more commonly used in patients with inflammatory arthritis; however, completed studies that have been performed in such patients have had limited outcome measurements and inadequate comparison groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=see_link\">",
"     \"Synovectomy for inflammatory arthritis of the knee\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arthroscopic synovectomy may be appropriate for patients with significant inflammatory signs or symptoms that are unresponsive to nonpharmacologic interventions, NSAIDs, intraarticular glucocorticoid injections, arthroscopic irrigation, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . Traditionally, patients with inflammatory arthritis and resistant monoarticular synovitis have been referred to orthopedists for synovectomy by arthrotomy; however, synovectomy using arthroscopic techniques affords several advantages, including less morbidity and improved rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthrotomy requires hospitalization whereas arthroscopy can be performed on an outpatient basis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After arthrotomy, patients commonly have fibroarthrosis with an average 10&ordm; to 20&ordm; loss of range of motion; in comparison, range of motion is preserved after arthroscopic synovectomies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/21,23\">",
"       21,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Synovectomy by arthrotomy requires both anterior and posterior incisions to completely accomplish the effects of synovectomy; arthroscopy requires three small portals [",
"      <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/21,23\">",
"       21,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TOTAL JOINT ARTHROPLASTY (REPLACEMENT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery should be considered in patients with severe symptomatic OA who have failed to respond to medical management (including arthroscopic procedures, if appropriate) and who have marked limitations in performing the activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/24\">",
"     24",
"    </a>",
"    ]. Despite the apparently greater need for prosthetic joint replacement in women than men, women are less likely to have discussed, to have been offered, or to have undergone joint replacement surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/25\">",
"     25",
"    </a>",
"    ]. Gender should not be a factor in determining whether surgery is offered, but at least one study utilizing &ldquo;standardized patients&rdquo; suggests that men are twice as likely as women to receive a recommendation for knee arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To maximize outcome and to minimize complications, surgery optimally should be performed before the development of significant deformities, joint instability, contractures, functional loss, or muscular atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The outcome is also affected by the patient&rsquo;s preoperative medical status and by postoperative management and rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients undergoing joint replacement surgery may have better functional outcomes if surgeons and the hospitals or surgical centers perform a greater volume of arthroplasties annually. This point was illustrated by a study of 932 patients in the United States whose knee pain, function, and satisfaction were assessed by self-report two years following total knee arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/31\">",
"     31",
"    </a>",
"    ]. Knee function was significantly worse in those operated upon by low-volume surgeons (performing fewer than six knee replacements per year) in low-volume centers (&le;25 knee replacements per year) than in those operated upon by higher-volume surgeons in higher-volume centers. Knee pain and patient satisfaction with the result of surgery were not significantly affected by surgeon or center knee replacement volume. High-volume surgeons and centers may also have lower perioperative mortality and selected complication rates for total joint arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Taken together, these data suggest that patients considered candidates for total joint replacement, particularly those referred for total knee replacement, should be directed to surgeons who perform such operations frequently in facilities that are also used regularly for the necessary procedure.",
"   </p>",
"   <p>",
"    The aims of surgical intervention include preservation or restoration of articular cartilage surfaces. This is accomplished by the realignment, fusion, or replacement of joints with prosthetic implants. Osteotomy is appropriate in selected patients who are not candidates for total joint arthroplasty; it provides pain relief and may prevent disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total joint arthroplasty provides marked pain relief and functional improvement in patients with severe hip or knee OA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/24,36\">",
"     24,36",
"    </a>",
"    ]. The indications, preoperative evaluation, choice of components, and perioperative management of total joint arthroplasty (replacement) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"     \"Total hip arthroplasty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=see_link\">",
"     \"Total knee arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement following total joint arthroplasty may be expected to progress for several months. This was illustrated in a study of patients undergoing total hip or knee replacement who were followed for up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/37\">",
"     37",
"    </a>",
"    ]. Most patients with total hip or knee arthroplasty for severe OA had improvement in pain which took",
"    <strong>",
"     one year",
"    </strong>",
"    or more to reach a maximal effect; the improvement was maintained for at least three years.",
"   </p>",
"   <p>",
"    Not all studies show this pattern of change in physical function with time. As an example, in a follow-up to the previously cited study of 222 patients who had total knee or hip replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/27\">",
"     27",
"    </a>",
"    ], functional improvement seen six months postoperatively did not increase during an additional 18 months of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A minority of patients undergoing total joint arthroplasty of the hip or knee are likely to subsequently need additional joint replacement. However, the contralateral limb appears to be a more likely site of such surgery than the ipsilateral lower extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/38\">",
"     38",
"    </a>",
"    ]. As an example, among a group of 117 patients who had total knee arthroplasty, total knee replacement on the opposite joint was performed in approximately 40 percent during the subsequent 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/39\">",
"     39",
"    </a>",
"    ]. Radiographs near the time of the index knee replacement were predictive of the likelihood of contralateral joint surgery. None of those with Kellgren-Lawrence radiographic grade 1 disease had contralateral knee replacement, while 60 percent of those with grade 4 damage did.",
"   </p>",
"   <p>",
"    Patients with bilateral disease may be offered sequential unilateral joint replacement or bilateral arthroplasty during one operative session. Which approach is preferred? There are limited data that directly address this issue. For total knee replacements (TKRs), one retrospective study compared the outcomes and costs associated with a single unilateral TKR with those associated with bilateral TKRs (198 versus 139 patients, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients undergoing unilateral TKR were significantly older than those selected for bilateral TKRs. A significantly greater proportion of patients who had bilateral TKRs were discharged to a rehabilitation facility rather than home (55 versus 33 percent). Thromboembolic events were also more frequent in the bilateral group (29 versus 6 percent); none were fatal during the hospital stay. Patient out-of-pocket costs did not differ significantly, but the median number of visits to health professionals was significantly greater for those who had unilateral TKR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     JOINT RESURFACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint resurfacing, specifically hip joint resurfacing or hip resurfacing arthroplasty, is an alternative to total hip replacement. Hip resurfacing arthroplasty preserves the femoral neck and uses a metal prosthesis to replace the femoral head. A metal acetabular component is utilized to create a metal-on-metal bearing surface. One uncontrolled series included 107 patients with a minimum of five years of postoperative follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/41\">",
"     41",
"    </a>",
"    ]. Although 93 percent were reported to have good or excellent clinical outcomes, 16 hips required revision surgery. The most common cause for revision was fracture of the femoral neck (12 hips), and the next most common was aseptic loosening (four hips). Although this procedure has been advocated for younger, more active patients, whether or not it is superior to total hip arthroplasty in this population is uncertain. The risk of complications is inversely related to the surgeon&rsquo;s experience with this technically demanding operation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CHONDROCYTE GRAFTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replacing localized regions of degenerated cartilage with autologous chondrocyte grafts has not been studied in large groups of patients. It is unlikely that this technique will be helpful in patients with advanced joint degeneration because of the large surface area that needs grafting in this setting. Most patients treated have been younger people with chondral defects caused by trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, chondrocyte grafts may be beneficial for selected patients with less severe, localized articular cartilage defects. Magnetic resonance imaging suggests that such chondrocyte grafts achieve a more uniform fill of the chondral defect and are less likely to produce osteophytes than microfracture techniques for promoting cartilage formation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARPOMETACARPAL OA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various surgical interventions have been used to treat pain and dysfunction arising from OA at the base of the thumb (carpometacarpal or trapeziometacarpal joint OA). A 2005 meta-analysis of seven studies that included a total of 384 patient compared pain and functional outcomes reported in patients who received one of the following surgical procedures: trapeziectomy, trapeziectomy with interpositional arthroplasty, trapeziectomy with ligament reconstruction, trapeziectomy with ligament reconstruction and tendon interposition, and joint replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12440/abstract/45\">",
"     45",
"    </a>",
"    ]. There was no clear advantage in terms of pain relief or functional improvement when the results of the different procedures were compared. Trapeziectomy alone had the fewest complications, while trapeziectomy with ligament reconstruction and tendon interposition had more than the other procedures. Patients who fail to respond to more conservative treatment may be candidates for trapeziectomy or for carpometacarpal joint replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"       \"Patient information: Hip replacement (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"       \"Patient information: Knee replacement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"       \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"       \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3012173\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical interventions for patients with osteoarthritis (OA) are generally reserved for those who have failed less invasive modes of therapy, although surgical interventions that utilize arthroscopic techniques for the treatment of OA of the knee, such as arthroscopic debridement with lavage and arthroscopic synovectomy, are controversial. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Arthroscopic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthroscopic irrigation may be warranted in selected patients with inflammatory symptoms who are refractory to NSAIDs or to intraarticular glucocorticoid injections. These patients may have debris and crystalline material; irrigation may remove these particles and may lead to improved symptoms and function. However, in studies of patients with knee OA, proof of greater benefit with arthroscopy than can be obtained by irrigation alone, sham procedures, or other controls is lacking. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Joint irrigation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Arthroscopic joint irrigation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Summary'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Tidal irrigation alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients may not respond to lavage alone because of advanced disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concomitant soft tissue problems, such as instability and degenerative tears of the menisci, loose bodies, or malalignment. The subset of patients with knee OA most likely to benefit from arthroscopic lavage and debridement include those patients with predominantly mechanical symptoms, with mild to moderate roentgenographic disease, and with shorter disease duration. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Arthroscopic debridement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No clinical trials have been performed that study the efficacy of arthroscopic synovectomy in patients with OA. Arthroscopic synovectomy may be appropriate for patients with significant inflammatory signs or symptoms that are unresponsive to nonpharmacologic interventions, NSAIDs, intraarticular glucocorticoid injections, arthroscopic irrigation, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Arthroscopic synovectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery should be considered in patients with severe symptomatic OA who have failed to respond to medical management (including arthroscopic procedures, if appropriate) and who have marked limitations in performing the activities of daily living. The aims of surgical intervention include preservation or restoration of articular cartilage surfaces, which is accomplished by the realignment, fusion, or replacement of joints with prosthetic implants. Osteotomy is appropriate in selected patients who are not candidates for total joint arthroplasty; it provides pain relief and may prevent disease progression. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Total joint arthroplasty (replacement)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hip joint resurfacing is an alternative to total hip replacement that has been advocated for younger, more active patients. It preserves the femoral neck and uses a metal prosthesis to replace the femoral head; a metal acetabular component is utilized to create a metal-on-metal bearing surface. Whether or not it is superior to total hip arthroplasty in this population is uncertain. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Joint resurfacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Replacing localized regions of degenerated cartilage with autologous chondrocyte grafts may be beneficial for selected patients with less severe, localized articular cartilage defects, but it requires further study. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Chondrocyte grafting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various surgical interventions have been used to treat pain and dysfunction arising from OA at the base of the thumb (carpometacarpal or trapeziometacarpal joint OA). Patients who fail to respond to more conservative treatment may be candidates for trapeziectomy or for carpometacarpal joint replacement. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Carpometacarpal OA'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/1\">",
"      Ike RW, Arnold WJ, Rothschild EW, Shaw HL. Tidal irrigation versus conservative medical management in patients with osteoarthritis of the knee: a prospective randomized study. Tidal Irrigation Cooperating Group. J Rheumatol 1992; 19:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/2\">",
"      Evans CH, Mears DC, McKnight JL. A preliminary ferrographic survey of the wear particles in human synovial fluid. Arthritis Rheum 1981; 24:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/3\">",
"      HORWITZ T. Bone and cartilage debris in the synovial membrane; its significance in the early diagnosis of neuro-arthropathy. J Bone Joint Surg Am 1948; 30A:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/4\">",
"      CHRISMAN OD, FESSEL JM, SOUTHWICK WO. EXPERIMENTAL PRODUCTION OF SYNOVITIS AND MARGINAL ARTICULAR EXOSTOSES IN THE KNEE JOINTS OF DOGS. Yale J Biol Med 1965; 37:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/5\">",
"      Evans CH, Mazzocchi RA, Nelson DD, Rubash HE. Experimental arthritis induced by intraarticular injection of allogenic cartilaginous particles into rabbit knees. Arthritis Rheum 1984; 27:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/6\">",
"      Evans CH, Mears DC, Cosgrove JL. Release of neutral proteinases from mononuclear phagocytes and synovial cells in response to cartilaginous wear particles in vitro. Biochim Biophys Acta 1981; 677:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/7\">",
"      Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/8\">",
"      Chang RW, Falconer J, Stulberg SD, et al. A randomized, controlled trial of arthroscopic surgery versus closed-needle joint lavage for patients with osteoarthritis of the knee. Arthritis Rheum 1993; 36:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/9\">",
"      Kalunian KC, Moreland LW, Klashman DJ, et al. Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial. Osteoarthritis Cartilage 2000; 8:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/10\">",
"      Klashman DJ, Moreland LW, Ike RW, Kalunian KC. Occult presence of CPPD crystals in patients undergoing arthroscopic knee irrigation for refractory pain related to osteoarthritis (abstract). Arthritis Rheum 1994; 37:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/11\">",
"      Ravaud P, Moulinier L, Giraudeau B, et al. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis Rheum 1999; 42:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/12\">",
"      Avouac J, Vicaut E, Bardin T, Richette P. Efficacy of joint lavage in knee osteoarthritis: meta-analysis of randomized controlled studies. Rheumatology (Oxford) 2010; 49:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/13\">",
"      Kirkley A, Birmingham TB, Litchfield RB, et al. A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2008; 359:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/14\">",
"      Edelson R, Burks RT, Bloebaum RD. Short-term effects of knee washout for osteoarthritis. Am J Sports Med 1995; 23:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/15\">",
"      Baumgaertner MR, Cannon WD Jr, Vittori JM, et al. Arthroscopic debridement of the arthritic knee. Clin Orthop Relat Res 1990; :197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/16\">",
"      Novak PJ, Bach BR Jr. Selection criteria for knee arthroscopy in the osteoarthritic patient. Orthop Rev 1993; 22:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/17\">",
"      Ogilvie-Harris DJ, Fitsialos DP. Arthroscopic management of the degenerative knee. Arthroscopy 1991; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/18\">",
"      Salisbury RB, Nottage WM, Gardner V. The effect of alignment on results in arthroscopic debridement of the degenerative knee. Clin Orthop Relat Res 1985; :268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/19\">",
"      Felson DT, Buckwalter J. Debridement and lavage for osteoarthritis of the knee. N Engl J Med 2002; 347:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/20\">",
"      Rand JA. Role of arthroscopy in osteoarthritis of the knee. Arthroscopy 1991; 7:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/21\">",
"      Arnold WJ. Office-based arthroscopy. Bull Rheum Dis 1992; 41:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/22\">",
"      Arnold WJ, Kalunian K. Arthroscopic synovectomy by rheumatologists: time for a new look. Arthritis Rheum 1989; 32:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/23\">",
"      Klein W, Jensen KU. Arthroscopic synovectomy of the knee joint: indication, technique, and follow-up results. Arthroscopy 1988; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/24\">",
"      Buckwalter JA, Lohmander S. Operative treatment of osteoarthrosis. Current practice and future development. J Bone Joint Surg Am 1994; 76:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/25\">",
"      Hawker GA, Wright JG, Coyte PC, et al. Differences between men and women in the rate of use of hip and knee arthroplasty. N Engl J Med 2000; 342:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/26\">",
"      Borkhoff CM, Hawker GA, Kreder HJ, et al. The effect of patients' sex on physicians' recommendations for total knee arthroplasty. CMAJ 2008; 178:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/27\">",
"      Fortin PR, Clarke AE, Joseph L, et al. Outcomes of total hip and knee replacement: preoperative functional status predicts outcomes at six months after surgery. Arthritis Rheum 1999; 42:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/28\">",
"      Fortin PR, Penrod JR, Clarke AE, et al. Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum 2002; 46:3327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/29\">",
"      Peterson MG, Hollenberg JP, Szatrowski TP, et al. Geographic variations in the rates of elective total hip and knee arthroplasties among Medicare beneficiaries in the United States. J Bone Joint Surg Am 1992; 74:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/30\">",
"      Lavernia CJ, Guzman JF. Relationship of surgical volume to short-term mortality, morbidity, and hospital charges in arthroplasty. J Arthroplasty 1995; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/31\">",
"      Katz JN, Mahomed NN, Baron JA, et al. Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older. Arthritis Rheum 2007; 56:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/32\">",
"      Katz JN, Barrett J, Mahomed NN, et al. Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am 2004; 86-A:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/33\">",
"      Taylor HD, Dennis DA, Crane HS. Relationship between mortality rates and hospital patient volume for Medicare patients undergoing major orthopaedic surgery of the hip, knee, spine, and femur. J Arthroplasty 1997; 12:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/34\">",
"      Hervey SL, Purves HR, Guller U, et al. Provider Volume of Total Knee Arthroplasties and Patient Outcomes in the HCUP-Nationwide Inpatient Sample. J Bone Joint Surg Am 2003; 85-A:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/35\">",
"      Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995; 38:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/36\">",
"      Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995; 38:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/37\">",
"      Kirwan JR, Currey HL, Freeman MA, et al. Overall long-term impact of total hip and knee joint replacement surgery on patients with osteoarthritis and rheumatoid arthritis. Br J Rheumatol 1994; 33:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/38\">",
"      Shakoor N, Block JA, Shott S, Case JP. Nonrandom evolution of end-stage osteoarthritis of the lower limbs. Arthritis Rheum 2002; 46:3185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/39\">",
"      McMahon M, Block JA. The risk of contralateral total knee arthroplasty after knee replacement for osteoarthritis. J Rheumatol 2003; 30:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/40\">",
"      March LM, Cross M, Tribe KL, et al. Two knees or not two knees? Patient costs and outcomes following bilateral and unilateral total knee joint replacement surgery for OA. Osteoarthritis Cartilage 2004; 12:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/41\">",
"      Steffen RT, Pandit HP, Palan J, et al. The five-year results of the Birmingham Hip Resurfacing arthroplasty: an independent series. J Bone Joint Surg Br 2008; 90:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/42\">",
"      Slover JD, Rubash HE. Hip resurfacing arthroplasty: time to consider it again? No. Instr Course Lect 2008; 57:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/43\">",
"      McNickle AG, L'Heureux DR, Yanke AB, Cole BJ. Outcomes of autologous chondrocyte implantation in a diverse patient population. Am J Sports Med 2009; 37:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/44\">",
"      Brown WE, Potter HG, Marx RG, et al. Magnetic resonance imaging appearance of cartilage repair in the knee. Clin Orthop Relat Res 2004; :214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12440/abstract/45\">",
"      Wajon A, Ada L, Edmunds I. Surgery for thumb (trapeziometacarpal joint) osteoarthritis. Cochrane Database Syst Rev 2005; :CD004631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5502 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12440=[""].join("\n");
var outline_f12_9_12440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3012173\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARTHROSCOPIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Joint irrigation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Arthroscopic joint irrigation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tidal irrigation alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arthroscopic debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Arthroscopic abrasion arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arthroscopic synovectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TOTAL JOINT ARTHROPLASTY (REPLACEMENT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      JOINT RESURFACING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CHONDROCYTE GRAFTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARPOMETACARPAL OA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3012173\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=related_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28565?source=related_link\">",
"      Synovectomy for inflammatory arthritis of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=related_link\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/6/17514?source=related_link\">",
"      Total knee arthroplasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_9_12441="Pelosi technique 3";
var content_f12_9_12441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Delivery and hysterotomy in the Pelosi cesarean technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A digital vertical extension of the hysterotomy incision is made. The vertical extension may be more efficient than traditional transverse extension. (B) The fetal head is delivered with the support of the surgeon's hand. (C) When head extraction cannot be accomplished using one hand assisted by concomitant fundal pressure, the soft vacuum cup can be employed. (D) Breech delivery is accomplished using standard extraction maneuvers. (E) Following spontaneous separation the placenta is removed by fundal pressure and light cord traction. (F) The hysterotomy is repaired either in situ using a single layer closure or by exteriorizing the uterus and using a double layer closure. When needed, hemostatic individual figure-of-eight sutures are also placed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marco Pelosi, MD and Marco Pelosi III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12441=[""].join("\n");
var outline_f12_9_12441=null;
var title_f12_9_12442="Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)";
var content_f12_9_12442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/9/12442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12442/contributors\">",
"     David A Greenwald, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12442/contributors\">",
"     Jonathan Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/9/12442/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12442/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/9/12442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/9/12442/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/9/12442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1213982066\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) includes visualization of the oropharynx, esophagus, stomach, and proximal duodenum, with real time assessment and interpretation of the findings encountered. A variety of technical and cognitive aspects must be mastered in order to perform a high quality examination. The basic technical components of upper endoscopy also serve as the platform upon which many therapeutic interventions are based.",
"   </p>",
"   <p>",
"    The elements of high quality performance in endoscopy have been well described and include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Prior to the procedure",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Appropriate indications and adherence to guidelines",
"     </li>",
"     <li>",
"      Suitable environment with adequate support team",
"     </li>",
"     <li>",
"      Strategies to minimize risk, including patient preparation and monitoring",
"     </li>",
"     <li>",
"      Well prepared, informed, and consented patients",
"     </li>",
"     <li>",
"      Correct selection of equipment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the procedure",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Appropriate use of",
"      <span class=\"nowrap\">",
"       sedation/analgesia",
"      </span>",
"     </li>",
"     <li>",
"      Comfortable oral and esophageal intubation with the endoscope",
"     </li>",
"     <li>",
"      Complete assessment of target organ(s)",
"     </li>",
"     <li>",
"      Recognition and documentation of all abnormalities",
"     </li>",
"     <li>",
"      Proper tissue sampling",
"     </li>",
"     <li>",
"      Use of appropriate therapy where indicated",
"     </li>",
"     <li>",
"      Avoiding, recognizing, and managing complications",
"     </li>",
"     <li>",
"      Reasonable procedure duration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the procedure",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Smooth recovery, explanation of procedure, and discharge",
"     </li>",
"     <li>",
"      Integrated pathology results",
"     </li>",
"     <li>",
"      Clear recommendations and follow-up plan",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review factors associated with performing an upper endoscopy including indications, patient preparation, technical aspects, tissue sampling, and complications. Detailed discussions of specific diagnostic and therapeutic interventions carried out during an upper endoscopy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link\">",
"     \"Treatment of active variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=see_link\">",
"     \"Overview of the treatment of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982073\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in upper endoscopy is appropriate patient selection. Patient selection must take into account not only the indication(s) for the procedure, but also patient-related factors such as comorbid illnesses that might increase the risk of performing an upper endoscopy or make the examination more difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012243\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;An upper endoscopy is indicated in the diagnostic evaluation of signs and symptoms of a wide variety of gastrointestinal disorders (",
"    <a class=\"graphic graphic_table graphicRef66596 \" href=\"UTD.htm?30/15/30972\">",
"     table 1",
"    </a>",
"    ). In addition, there are multiple therapeutic indications for upper endoscopy.",
"   </p>",
"   <p>",
"    In 2000, the American Society of Gastrointestinal Endoscopy (ASGE) issued guidelines regarding the performance of upper gastrointestinal (GI) endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/3\">",
"     3",
"    </a>",
"    ]. In general, they recommend upper endoscopy if the results are likely to influence management of the patient, if empiric treatment for a suspected benign disorder has been unsuccessful, if the procedure can be used as an alternative to radiographic evaluation, or if a therapeutic maneuver may be needed. In addition, upper endoscopy is indicated if the results would affect the management of other diseases (eg, a patient with a history of upper GI bleeding who requires anticoagulation or treatment with a nonsteroidal antiinflammatory drug).",
"   </p>",
"   <p>",
"    The ASGE guidelines note that upper endoscopy is generally not indicated when the results will not affect management or for periodic surveillance of healed benign lesions, unless surveillance of a premalignant condition is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012372\">",
"    <span class=\"h3\">",
"     Diagnostic examinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many upper endoscopies are carried out for the evaluation of symptoms or to investigate abnormal findings on GI tract radiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper gastrointestinal symptoms &mdash; Upper endoscopy is indicated for the evaluation of patients with upper abdominal symptoms (eg, pain, nausea) that persist despite an adequate trial of therapy, whose symptoms are associated with other signs or symptoms that suggest serious organic disease such as weight loss, or who are over the age of 45 years. Upper endoscopy is also indicated for the evaluation of dysphagia, odynophagia, esophageal reflux that is persistent or recurrent despite adequate therapy, or persistent vomiting of an unknown cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=see_link\">",
"       \"Approach to the patient with dyspepsia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Upper gastrointestinal bleeding &mdash; Active or recent upper GI bleeding is another indication for upper endoscopy. In addition, upper endoscopy should be considered for patients with chronic blood loss and iron deficiency anemia with a clinically suspected upper GI source or if a colonoscopy is negative. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H9942984#H9942984\">",
"       \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Upper endoscopy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"       \"Evaluation of obscure gastrointestinal bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of occult gastrointestinal bleeding\", section on 'Upper endoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal imaging",
"      <strong>",
"       &mdash;",
"      </strong>",
"      Upper endoscopy is indicated for the evaluation of lesions seen on upper GI tract radiology (eg, suspected neoplasms, ulcers, strictures or obstructions). However, upper endoscopy is generally not indicated for the evaluation of asymptomatic or uncomplicated sliding hiatus hernias, radiologically demonstrated duodenal ulcers that respond to ulcer therapy, or the finding of a deformed duodenal bulb that is asymptomatic or has responded to ulcer therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75116262\">",
"    <span class=\"h3\">",
"     Caustic ingestions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute caustic ingestions should undergo upper endoscopy to assess the degree of injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40551?source=see_link&amp;anchor=H11#H11\">",
"     \"Caustic esophageal injury in adults\", section on 'Endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012411\">",
"    <span class=\"h3\">",
"     Screening/surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is recommended that patients with Barrett's esophagus undergo endoscopic surveillance. This recommendation is based upon the assumptions that Barrett's esophagus adversely influences survival and that surveillance can reduce mortality. However, a survival benefit in patients undergoing surveillance has not been demonstrated in randomized prospective trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of Barrett's esophagus\", section on 'Endoscopic surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper endoscopy can be used to screen patients for gastric cancer, though consensus has not been achieved on screening recommendations. However, some form of screening has been proposed in several subgroups of patients in whom the risk of gastric cancer is particularly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/4\">",
"     4",
"    </a>",
"    ]. These include elderly patients with atrophic gastritis or pernicious anemia, those who have undergone partial gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], those with a sporadic gastric adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/7\">",
"     7",
"    </a>",
"    ], immigrant ethnic populations from countries with high rates of gastric cancer (",
"    <a class=\"graphic graphic_table graphicRef60151 \" href=\"UTD.htm?34/54/35692\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/5-14\">",
"     5-14",
"    </a>",
"    ], and patients with familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer (particularly if gastric cancer has occurred in the kindred) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=see_link\">",
"     \"Screening and prevention of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper endoscopy is also used to screen patients with portal hypertension for the presence of esophageal varices and to screen patients with a history of a caustic ingestion for esophageal squamous cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\", section on 'Screening for varices'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40551?source=see_link&amp;anchor=H16#H16\">",
"     \"Caustic esophageal injury in adults\", section on 'Esophageal squamous cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012364\">",
"    <span class=\"h3\">",
"     Planned therapeutic intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic indications for upper endoscopy include (see",
"    <a class=\"local\" href=\"#H67011595\">",
"     'Diagnostic and therapeutic maneuvers'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of bleeding lesions (ulcers, angiodysplasias, varices)",
"     </li>",
"     <li>",
"      Prophylactic banding of esophageal varices",
"     </li>",
"     <li>",
"      Removal of foreign bodies",
"     </li>",
"     <li>",
"      Placement of feeding or drainage tubes",
"     </li>",
"     <li>",
"      Removal of selected polypoid lesions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=see_link\">",
"       \"Gastric polyps\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dilation of stenotic lesions",
"     </li>",
"     <li>",
"      Management of achalasia",
"     </li>",
"     <li>",
"      Palliation of stenosing neoplasms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67011540\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any procedure, patients in whom the risks of upper endoscopy are believed to outweigh the benefits should not undergo the procedure. Other contraindications include the inability of the patient to cooperate with the procedure despite adequate attempts at",
"    <span class=\"nowrap\">",
"     sedation/anesthesia,",
"    </span>",
"    an inability to obtain informed consent, or the presence of a known or suspected perforated viscus (unless the examination is being done to treat the perforation). Failure to comply with dietary restrictions prior to endoscopy is a relative contraindication. (See",
"    <a class=\"local\" href=\"#H67012131\">",
"     'Diet'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One question that often comes up is when is it safe to perform an upper endoscopy in a patient who has had a recent myocardial infarction (MI). In a patient who needs an",
"    <span class=\"nowrap\">",
"     urgent/emergent",
"    </span>",
"    endoscopy (eg, overt upper GI bleeding), endoscopy should not be delayed in a hemodynamically stable patient with a recent MI. A decision analysis suggests that this approach is preferable to proceeding with cardiac catheterization in patients with overt (but not occult) GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to elective procedures, there are no firm recommendations. The American Heart Association recommends waiting four to six weeks for noncardiac surgery following an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/17\">",
"     17",
"    </a>",
"    ]. One factor that complicates endoscopy in this setting is that patients are likely to be taking antiplatelet agents. The management of these agents around the time of endoscopy is discussed in elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether the procedure is emergent or elective, decisions regarding the timing of endoscopy and the management of antiplatelet agents in such patients should involve both the gastroenterologist(s) and cardiologist(s) caring for the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012257\">",
"    <span class=\"h2\">",
"     Important considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the procedure, patients should be evaluated for other factors that may affect the ability to safely and successfully perform an upper endoscopy, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic considerations such as a small mouth or a limited range of motion in the jaw (factors that may make it difficult to insert the protective mouth piece), a limited range of motion of the neck that may make correct patient positioning difficult, or the presence of a Zenker's diverticulum, which increases the risk of esophageal perforation during esophageal intubation",
"     </li>",
"     <li>",
"      Comorbid illnesses that may increase the risks associated with sedation",
"     </li>",
"     <li>",
"      Use of medications such as benzodiazepines or narcotics that may increase a patient's tolerance to the effects of sedation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982080\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012131\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to elective upper endoscopy, patients typically take no food by mouth for four to eight hours, and sometimes longer if there is known or suspected delayed gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/18\">",
"     18",
"    </a>",
"    ]. Alternatively, clear liquids can be taken up to two hours before endoscopy (American Society of Anesthesiologists guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/19\">",
"     19",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75116545\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medications can be continued up to the time of endoscopy and are usually taken with a small sip of water. Some medications may need to be adjusted prior to upper endoscopy, such as medications for diabetes, due to decreased oral intake around the time of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012139\">",
"    <span class=\"h2\">",
"     Management of anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding the management of antiplatelet agents or anticoagulants must take into account the risk of bleeding engendered by maintaining the patient on the agent through the procedure and the risk of a thromboembolic event if the agent is discontinued in the periprocedural period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/20\">",
"     20",
"    </a>",
"    ]. In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and NSAIDs can be continued safely in patients having upper endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75116514\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines exist for the use of antibiotic prophylaxis in endoscopy. Because the risk of infection related to routine diagnostic upper endoscopy is low, antibiotic prophylaxis is not recommended. However, antibiotic prophylaxis is recommended for patients undergoing endoscopy for variceal bleeding or percutaneous endoscopic gastrostomy tube placement (",
"    <a class=\"graphic graphic_table graphicRef51133 \" href=\"UTD.htm?30/19/31037\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54121 \" href=\"UTD.htm?13/60/14285\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67012147\">",
"    <span class=\"h1\">",
"     SEDATION ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of the patient's sedation needs and risks prior to the examination should be done [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. This includes taking a complete history of factors that might make sedation more difficult, such as prior difficulties with sedation, narcotic or benzodiazepine use, diminished mental capacity, and agitation or severe anxiety. It also includes considering whether the patient has any characteristics that pose an increased risk for aspiration (eg, ascites, non-empty stomach, active bleeding), difficult airway management (eg, obesity, non-visibility of the uvula, prior history of difficult intubation), or increased cardiopulmonary complications of endoscopy (eg, co-morbidities, obesity, older age, etc.). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67011854\">",
"    <span class=\"h1\">",
"     INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent is a process, not merely a form, and it is based upon all of the interactions between the healthcare provider and the patient. Informed consent includes a clear and complete explanation of all portions of the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Five essential elements to discuss in preparation for upper endoscopy include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nature of the procedure",
"     </li>",
"     <li>",
"      Benefits",
"     </li>",
"     <li>",
"      Risks",
"     </li>",
"     <li>",
"      Alternatives",
"     </li>",
"     <li>",
"      Limitations of procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of clear and simple language is critical during the process of obtaining consent. For example, upper endoscopy might be explained as \"a procedure in which a doctor passes a flexible tube with a light and a camera though your mouth and a swallowing tube into your stomach and the upper part of your small intestine.\" A discussion of the possible risks of upper endoscopy, including bleeding, perforation, and missed lesions must occur, while at the same time placing the risks and benefits of the proposed procedure in balance and in a framework the patient can understand. (See",
"    <a class=\"local\" href=\"#H67011650\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Written documentation of the discussion of consent is mandatory. In addition, when needed, the use of translators and materials written in a language in which the patient is fluent are also important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67011548\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine upper endoscopy is performed using a high-definition white-light endoscope. In addition, multiple options are available to enhance visualization during endoscopy, though many require specialized equipment and training. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=see_link\">",
"     \"Confocal laser endomicroscopy and endocytoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=see_link\">",
"     \"Autofluorescence endoscopy for Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine upper gastrointestinal endoscopy may be broken down into its component parts:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral intubation with the endoscope",
"     </li>",
"     <li>",
"      Oropharyngeal examination",
"     </li>",
"     <li>",
"      Esophageal examination",
"     </li>",
"     <li>",
"      Examination of the esophagogastric junction (EGJ, also referred to as the gastroesophageal junction)",
"     </li>",
"     <li>",
"      Gastric examination, including retroflexion",
"     </li>",
"     <li>",
"      Traversing the pylorus",
"     </li>",
"     <li>",
"      Duodenal examination",
"     </li>",
"     <li>",
"      Tissue sampling",
"     </li>",
"     <li>",
"      Therapeutic maneuvers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982087\">",
"    <span class=\"h2\">",
"     Intubation with the endoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many centers begin the procedure by applying topical pharyngeal anesthesia with an agent such as a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    spray. Others omit this step since it may not improve patient tolerance of the procedure and since it is associated with methemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/26\">",
"     26",
"    </a>",
"    ]. Finally, some endoscopists apply a small amount of benzocaine gel for topical pharyngeal anesthesia. (See",
"    <a class=\"local\" href=\"#H61432890\">",
"     'Methemoglobinemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For upper gastrointestinal endoscopy, patients are typically placed on their left side with their neck flexed forward. A simulation of the maneuver that will be necessary to pass the endoscope from the mouth to the upper esophageal sphincter is recommended to assure proper orientation of all equipment. The upper endoscope is introduced into the mouth under direct visualization, allowing for limited visualization of the tongue, other structures in the mouth, and ultimately the hypopharynx. The endoscopist can often view the epiglottis, the vocal cords, both piriform sinuses, and the arytenoid cartilages (",
"    <a class=\"graphic graphic_picture graphicRef82592 \" href=\"UTD.htm?42/25/43410\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    On the monitor, the cricopharyngeus muscle and esophageal orifice appear below the opening to the trachea, seemingly between the piriform sinuses. The endoscope is passed posteriorly toward the upper esophageal sphincter, which is at the level of the thyroid cartilage, 15 to 18 cm from the incisors. The upper esophageal sphincter is passed under direct visualization, often with the assistance of air insufflation and slight application of pressure.",
"   </p>",
"   <p>",
"    Esophageal intubation should be done slowly and gently, in part to avoid intubation of a Zenker's diverticulum, since doing so can lead to a perforation. A Zenker's diverticulum is an outpouching of the posterior oropharynx just proximal to the upper esophageal sphincter caused by decreased compliance of the upper esophageal sphincter. Care must also be taken in patients with known or suspected proximal esophageal strictures, which can make esophageal intubation difficult and can increase the risk of perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=see_link\">",
"     \"Zenker's diverticulum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982094\">",
"    <span class=\"h2\">",
"     Esophagus and esophagogastric junction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following intubation of the esophagus, the tubular esophagus is examined. The esophagus is typically about 25 cm in length. The examination should be carried out slowly and with adequate air insufflation to ensure complete visualization. Elements to note include the color of the mucosa and evidence of erythema, erosions, ulcers, strictures, rings, webs, varices, or diverticula.",
"   </p>",
"   <p>",
"    The esophagogastric junction is generally about 40 cm from the incisors. There are both anatomic and histologic markers that separate the esophagus from the stomach. However, landmarks differentiating the esophagus from the stomach may be difficult to identify due to movement of the esophagus and stomach during the examination. The top of the gastric folds is the landmark generally believed to represent the esophagogastric junction. In patients without Barrett's esophagus, this is also the area of the squamocolumnar junction. The squamocolumnar junction is the area where the squamous epithelial lining of the esophagus meets the columnar lining of the stomach. Because this transition from squamous to columnar epithelium is typically uneven around the circumference of the lumen, it is also referred to as the z-line. The transition from squamous to columnar epithelium results in a color change. The columnar mucosa of the stomach is salmon-colored, whereas the squamous mucosa is pale pink (",
"    <a class=\"graphic graphic_picture graphicRef83182 \" href=\"UTD.htm?0/44/706\">",
"     picture 2",
"    </a>",
"    ). In patients without a hiatus hernia, the esophagogastric junction also corresponds with the lower esophageal sphincter, though the lower esophageal sphincter cannot be seen endoscopically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=see_link&amp;anchor=H2#H2\">",
"     \"Hiatus hernia\", section on 'Anatomy and physiology of the gastroesophageal junction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hiatus hernias are frequently identified during upper endoscopy. A hiatus hernia is a condition where some portion of the stomach has herniated through the esophageal hiatus in the crural diaphragm. In this situation, the columnar-lined mucosa and top of the gastric folds will be seen proximal to the extrinsic narrowing of the lumen caused by the diaphragmatic pinch. Hiatus hernias may be seen during retroflexed exanimation of the stomach as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=see_link&amp;anchor=H3#H3\">",
"     \"Hiatus hernia\", section on 'Types of hiatal hernia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982101\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach is entered after passing the region of the esophagogastric junction. Initial visualization is usually of the relatively large folds of the greater curvature of the stomach (",
"    <a class=\"graphic graphic_picture graphicRef55359 \" href=\"UTD.htm?10/7/10356\">",
"     picture 3",
"    </a>",
"    ). The examination usually proceeds along the greater curvature of the stomach towards the pylorus (",
"    <a class=\"graphic graphic_figure graphicRef68173 \" href=\"UTD.htm?31/53/32595\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Certain techniques improve examination of the stomach. First, it is important to avoid full insufflation of the stomach initially, as it may induce retching or belching. Second, suctioning the pool of fluid that is often seen in the fundus upon entering the stomach improves visualization of the area. This also minimizes the risk of reflux of gastric fluid and possible aspiration. A plastic trap can be placed in line with the suction tubing to collect this fluid for pH analysis if needed. However, care should be taken to avoid applying suction to the mucosa, as doing so may create suction artifacts that appear as abnormal mucosa. In addition, since any contact between the endoscope and the mucosa can result in trauma, it is best to examine the mucosa throughout the upper GI tract while avoiding contact with the mucosa.",
"   </p>",
"   <p>",
"    While all areas of the stomach should be carefully examined, particular attention should be paid to the area of the angularis along the lesser curvature as it is often the site of pathology.",
"   </p>",
"   <p>",
"    Adequate visualization of the proximal stomach and esophagogastric junction is achieved through retroflexion. Retroflexion allows the endoscopist to see areas that are not well visualized during the initial direct examination (",
"    <a class=\"graphic graphic_figure graphicRef68753 \" href=\"UTD.htm?40/37/41554\">",
"     figure 2",
"    </a>",
"    ). The technique involves the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distending the stomach with air",
"     </li>",
"     <li>",
"      Advancing the endoscope to the region of the angularis in the lesser curvature in the antrum",
"     </li>",
"     <li>",
"      Turning the endoscope up-down dial to the maximal up position to achieve a 140 to 160 degree bend at the tip of the endoscope",
"     </li>",
"     <li>",
"      Many recommend locking the wheels of the endoscope to increase stiffness of the tip of the endoscope",
"     </li>",
"     <li>",
"      Withdrawing the endoscope in order to pull the tip of the endoscope toward the esophagogastric junction (",
"      <a class=\"graphic graphic_picture graphicRef69189 \" href=\"UTD.htm?17/47/18162\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rotating the endoscope to obtain a 360 degree view of the upper stomach",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hiatus hernias are particularly easy to see when the endoscope is in the retroflexed position (",
"    <a class=\"graphic graphic_picture graphicRef83183 \" href=\"UTD.htm?37/2/37922\">",
"     picture 5",
"    </a>",
"    ). It is important to note that items placed through the endoscope's accessory channel, such as a biopsy forceps, may be difficult to use when the endoscope is in the retroflexed position. In addition, care is required to ensure that the retroflexed endoscope does not become entrapped within a hiatus hernia or in the esophagus. This is normally done by making sure that the retroflexed scope is not pulled into the hernia or the esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982108\">",
"    <span class=\"h2\">",
"     Pyloric intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Next, the pylorus traversed under direct visualization (",
"    <a class=\"graphic graphic_picture graphicRef82398 \" href=\"UTD.htm?32/30/33263\">",
"     picture 6",
"    </a>",
"    ). Opening the pylorus for passage of the endoscope sometimes requires air insufflation, and patience may be required in patients who have particularly active or motile pyloric regions. Some patients have \"J-shaped\" stomachs, and this may increase the difficulty of intubating the pylorus due to the extreme angulation of the endoscope that may be required. Attempts to traverse the pylorus in such patients may sometimes result in significant looping in which the shaft of the endoscope presses on the greater curvature of the stomach. The pressure applied to the gastric wall by the loop can result in patient discomfort. Removing air from the stomach may help with passage in such cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982115\">",
"    <span class=\"h2\">",
"     Duodenum",
"    </span>",
"    &nbsp;&mdash;&nbsp;After passing through the pylorus, the endoscope enters the duodenal bulb. The endoscope is then advanced through the duodenal sweep and into the second portion of the duodenum. The duodenal bulb is often devoid of characteristic features, though there may be raised bumps and polypoid areas, representing either prominent Brunner's glands or heterotopic foci of gastric mucosa. The duodenum distal to the bulb has distinctive circular rings called valvulae conniventes (",
"    <a class=\"graphic graphic_picture graphicRef61994 \" href=\"UTD.htm?7/7/7284\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ampulla of Vater is found in the second portion of the duodenum and is the site where the common bile duct and pancreatic duct empty into the duodenum. While the ampulla may be seen with a standard forward-viewing endoscope, a more complete examination of the ampulla requires the use of a side-viewing duodenoscope (the same endoscope used for endoscopic retrograde cholangiopancreatography). This is not done routinely as part of an upper endoscopy and requires specialized skills and equipment. However, it may be required for some patients, such as those with familial adenomatous polyposis who are undergoing screening for ampullary adenomas. If examination of the ampulla is required, the examination should be performed with an endoscopist who is trained in the use of a side-viewing duodenoscope. In addition, the need for ampullary visualization should be communicated to the endoscopist prior to the procedure to ensure that the appropriate equipment is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67011595\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC AND THERAPEUTIC MANEUVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of diagnostic and therapeutic maneuvers can be carried out during upper endoscopy. The most common diagnostic maneuver is tissue sampling. Other interventions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic hemostasis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the treatment of bleeding peptic ulcers\", section on 'Endoscopic therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of active variceal hemorrhage\", section on 'Endoscopic treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=see_link&amp;anchor=H26#H26\">",
"       \"Angiodysplasia of the gastrointestinal tract\", section on 'Endoscopic treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"       \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43317?source=see_link&amp;anchor=H8#H8\">",
"       \"Mallory-Weiss syndrome\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"       \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dilation of esophageal strictures, gastric outlet stenoses, anastomotic strictures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"       \"Management of benign esophageal strictures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link&amp;anchor=H26#H26\">",
"       \"Gastric outlet obstruction in adults\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28489?source=see_link&amp;anchor=H14#H14\">",
"       \"Endoscopy in patients who have undergone bariatric surgery\", section on 'Stomal stenosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stent placement for benign or malignant disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=see_link\">",
"       \"Expandable stents in the treatment of esophageal obstruction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=see_link\">",
"       \"Endoscopic palliation of esophageal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=see_link\">",
"       \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ablation of Barrett's esophagus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=see_link\">",
"       \"Radiofrequency ablation for Barrett's esophagus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"       \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Endoscopic mucosal resection of gastrointestinal tumors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"       \"Overview of endoscopic resection of gastrointestinal tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Percutaneous endoscopic gastrostomy tube placement (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34937?source=see_link\">",
"       \"Prevention and management of complications from percutaneous endoscopic gastrostomy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Foreign body removal (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=see_link\">",
"       \"Ingested foreign bodies and food impactions in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"       \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pneumatic dilation or botulinum toxin injection for achalasia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=see_link\">",
"       \"Pneumatic dilation and botulinum toxin injection for achalasia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Placement of a wireless video capsule endoscope (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link&amp;anchor=H8#H8\">",
"       \"Wireless video capsule endoscopy\", section on 'Capsule ingestion'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Placement of esophageal acid monitoring devices (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Ambulatory esophageal pH monitoring'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Endoscopic therapy for gastroesophageal reflux (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25688?source=see_link\">",
"       \"Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Endoscopic treatment of a Zenker's diverticulum (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=see_link&amp;anchor=H9#H9\">",
"       \"Zenker's diverticulum\", section on 'Flexible endoscopic approaches'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67011611\">",
"    <span class=\"h2\">",
"     Tissue sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue sampling is an important part of many upper endoscopic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This is highlighted by the fact that training guidelines emphasize the requirement that anyone performing diagnostic upper endoscopy masters standard techniques of tissue sampling, which include biopsies, brushings of the mucosal surface, and polypectomy. Specimens obtained during procedures can be sent for histologic, cytologic, or microbiologic analysis, depending on the type of sample and clinical scenario.",
"   </p>",
"   <p>",
"    While making the visual assessment and deciding what sampling to perform, endoscopists should always keep in mind the clinical questions which prompted the procedure in the first place.",
"   </p>",
"   <p>",
"    When submitting samples, it is helpful to provide the pathologist, cytologist, or microbiologist with details such as the clinical history, specimen-specific location and appearance, and the question to be answered. Including the endoscopy report and photographs of the area in question can also be very helpful.",
"   </p>",
"   <p>",
"    The techniques of tissue sampling are usually straightforward:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopsy: a biopsy forceps is placed though the accessory channel of the endoscope, advanced to the target area, and the forceps is opened and closed to obtain a pinch biopsy. Many forceps have a \"spike\" that allows for the acquisition of more than one sample at a time.",
"      <br/>",
"      <br/>",
"      The tubular esophagus may be difficult to biopsy because the forceps comes out of the accessory channel parallel to the wall of the esophagus. This problem can be solved by the \"turn-in\" technique, where the tip of the endoscope is turned to be more perpendicular to the wall of the esophagus (or anywhere in the upper GI tract where this is an issue), allowing for a more direct angle in which to obtain a biopsy. This technique may be augmented by suctioning of the mucosa into the biopsy forceps before tissue acquisition, allowing for a larger sample to be obtained with each \"bite\" of the biopsy forceps.",
"      <br/>",
"      <br/>",
"      Typically, biopsy forceps can only sample mucosal lesions. If a submucosal lesion is encountered, it may be possible to perform stacked or tunneled biopsies in which the same location is biopsied multiple times with the hope of obtaining deeper samples. This frequently is unsuccessful and increases the risk of perforation (especially in the esophagus), so it should be done with extreme caution.",
"     </li>",
"     <li>",
"      Brushings: a brush within a sheath is placed though the accessory channel of the endoscope and advanced to the target area. The brush head is advanced out of the sheath, and the endoscopist gently brushes the area of interest.",
"     </li>",
"     <li>",
"      Polypectomy: polypectomy is carried out in a manner similar to that used during colonoscopy. Small polyps may be removed using a biopsy forceps. Larger polyps can be removed using snares that are passed down the accessory channel of the endoscope. Lesions larger than about 2 cm may require removal using specialized techniques. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of endoscopic resection of gastrointestinal tumors\", section on 'ER Techniques'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982129\">",
"    <span class=\"h1\">",
"     PHOTODOCUMENTATION AND REPORTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All endoscopic procedures should include a complete report detailing the extent of the tissue examined and all normal and abnormal findings encountered. Photodocumentation greatly enhances the record and should be included when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213982136\">",
"    <span class=\"h1\">",
"     TROUBLESHOOTING COMMON PROBLEMS IN UPPER ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some problems occur frequently during upper gastrointestinal endoscopy and may have straightforward solutions. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessively motility in the stomach or small bowel may make careful examination difficult. While patience may be all that is necessary to allow the bowel to \"quiet\" and allow the entire examination to be completed, the use of medications to slow the bowel, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      (0.5mg IV), is an option. This may be particularly helpful when therapeutic maneuvers are being carried out (eg, argon plasma coagulation of an angiodysplasia).",
"     </li>",
"     <li>",
"      Bubbles and excessive mucus may obscure the view of portions of the upper GI tract during endoscopy; adequate washing using an irrigating syringe or irrigating device is often sufficient. Agents that lower the surface tension of bubbles (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"       simethicone",
"      </a>",
"      ) and mucolytic agents (eg, N-acetylcysteine) may be useful.",
"     </li>",
"     <li>",
"      Residual material in the stomach needs to be cleared for adequate visualization; again, copious irrigation is often sufficient. Prokinetic agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (10 mg IV) given 30 to 90 minutes prior to endoscopy may facilitate passage of retained debris or blood. Residual gastric contents not only impede complete visualization but also increased the risk of the complication of aspiration. Specialized suction devices are also available to help clear the stomach. These are most often used in the setting of upper gastrointestinal bleeding.",
"     </li>",
"     <li>",
"      Abnormal anatomy (eg, a J-shaped stomach in the chest) or surgically altered anatomy (eg, bariatric surgery) may make completion of upper endoscopy more difficult. Specific maneuvers, such as changing the patient's position or the application of external abdominal pressure to \"splint\" the stomach, may facilitate instrument passage in some situations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28489?source=see_link\">",
"       \"Endoscopy in patients who have undergone bariatric surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67011650\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of upper endoscopy include complications related to sedation, complications related to the endoscopy, and complications related to diagnostic and therapeutic maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Data are limited regarding the overall risk of complications. In a large survey from 1974 that was based upon 200,000 upper endoscopies, the overall complication rate was 0.13 percent, and the mortality rate was 0.004 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequent studies have estimated complication rates of 0.15 percent overall [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/32\">",
"     32",
"    </a>",
"    ] and 0.0002 percent for diagnostic endoscopy without therapeutic maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61432870\">",
"    <span class=\"h2\">",
"     Complications related to sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent and serious complications of procedural sedation are cardiopulmonary. Risk factors for the development of cardiopulmonary complications of endoscopy include advanced age, underlying comorbid illness (especially pulmonary disease), dementia, anemia, obesity, and endoscopy performed for emergent indications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/22\">",
"     22",
"    </a>",
"    ]. Adverse events resulting from oversedation include hypoxemia, hypoventilation, airway obstruction, hypotension, vasovagal episodes, arrhythmias, and aspiration. The frequency of such unplanned cardiopulmonary events has been shown to be associated with increasing American Society of Anesthesiologists (ASA) scores [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall incidence of cardiopulmonary complications is low. In a prospective survey of 14,149 upper endoscopies and a retrospective study of 21,011 endoscopic procedures, the rates of early cardiopulmonary events were 2 to 5.4 per 1000 cases and mortality rates, which included cases of aspiration pneumonia, pulmonary embolism, and myocardial infarction, were 0.3 to 0.5 per 1000 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28310?source=see_link\">",
"     \"Complications of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61432890\">",
"    <span class=\"h2\">",
"     Methemoglobinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methemoglobin is an altered state of hemoglobin in which the ferrous (Fe2+) irons of heme are oxidized to the ferric (Fe3+) state. The ferric hemes of methemoglobin are",
"    <strong>",
"     unable",
"    </strong>",
"    to bind oxygen. In addition, the oxygen affinity of any accompanying ferrous hemes in the hemoglobin tetramer is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/36\">",
"     36",
"    </a>",
"    ]; as a result, the oxygen dissociation curve is \"left-shifted,\" and oxygen delivery to the tissues is impaired (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Topical anesthetics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    , are a common cause of methemoglobinemia. Methemoglobinemia may be clinically suspected in this setting by the presence of clinical \"cyanosis\" and a normal arterial PO2 (PaO2) obtained by arterial blood gas assessment,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of \"chocolate brown blood\" [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61433415\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding rarely occurs following diagnostic upper endoscopy. While the risk may be increased in patients with thrombocytopenia or coagulopathies, diagnostic upper endoscopy is generally thought to be safe in patients with platelet counts as low as 20,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk of bleeding is increased with therapeutic maneuvers such as esophageal dilation, percutaneous endoscopic gastrostomy tube placement, or endoscopic mucosal resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of endoscopic esophageal stricture dilation\", section on 'Hemorrhage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link&amp;anchor=H1942073#H1942073\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34937?source=see_link\">",
"     \"Prevention and management of complications from percutaneous endoscopic gastrostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61432898\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy is the most common cause of esophageal perforation. It is more common when therapeutic maneuvers are carried out and in patients with esophageal diverticula. The estimated risk of esophageal perforation varies with the procedure being performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/9/12442/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnostic endoscopy with a flexible endoscope: 0.03 percent",
"     </li>",
"     <li>",
"      Diagnostic endoscopy with a rigid endoscope: 0.11 percent",
"     </li>",
"     <li>",
"      Stricture dilation: 0.09 to 2.2 percent",
"     </li>",
"     <li>",
"      Sclerotherapy: 1 to 5 percent",
"     </li>",
"     <li>",
"      Pneumatic dilation for achalasia: 2 to 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and management of esophageal perforations is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=see_link\">",
"     \"Complications of endoscopic esophageal stricture dilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications of endoscopic esophageal stricture dilation\", section on 'Esophageal perforation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/329?source=see_link\">",
"     \"Surgical management of esophageal perforation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61433290\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infection related to gastrointestinal endoscopy is low, though there have been cases of hepatitis B, hepatitis C, and bacterial transmission related to breaches in protocols for proper endoscope disinfection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6312?source=see_link\">",
"     \"Endoscope disinfection\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H75116514\">",
"     'Antibiotic prophylaxis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67011687\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper endoscopy (esophagogastroduodenoscopy, EGD) includes visualization of the oropharynx, esophagus, stomach, and proximal duodenum, with real time assessment and interpretation of the findings encountered. (See",
"      <a class=\"local\" href=\"#H1213982066\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upper gastrointestinal endoscopy is indicated in the diagnostic evaluation of signs and symptoms of a wide variety of gastrointestinal disorders as well as for therapeutic interventions (",
"      <a class=\"graphic graphic_table graphicRef66596 \" href=\"UTD.htm?30/15/30972\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H67012243\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to elective upper gastrointestinal endoscopy, patients typically take nothing by mouth for four to eight hours and sometimes longer if there is known or suspected delayed gastric emptying. Most medications can be continued up to the time of endoscopy and are usually taken with a small sip of water. Whether to stop antiplatelet agents or anticoagulants must take into account the procedure-related risk of bleeding and the risk of periprocedural thrombosis. Antibiotic prophylaxis is not required for the majority of patients undergoing upper endoscopy (",
"      <a class=\"graphic graphic_table graphicRef51133 \" href=\"UTD.htm?30/19/31037\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54121 \" href=\"UTD.htm?13/60/14285\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1213982080\">",
"       'Patient preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine upper endoscopy is performed using a high-definition white-light endoscope. In addition, multiple options are available to enhance visualization during endoscopy, though many require specialized equipment and training. (See",
"      <a class=\"local\" href=\"#H67011548\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of diagnostic and therapeutic maneuvers can be carried out during upper endoscopy. The most common diagnostic maneuver is tissue sampling. (See",
"      <a class=\"local\" href=\"#H67011595\">",
"       'Diagnostic and therapeutic maneuvers'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other interventions include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Endoscopic hemostasis",
"     </li>",
"     <li>",
"      Dilation of esophageal strictures, gastric outlet stenoses, anastomotic strictures",
"     </li>",
"     <li>",
"      Stent placement for benign or malignant disease",
"     </li>",
"     <li>",
"      Ablation of Barrett's esophagus",
"     </li>",
"     <li>",
"      Endoscopic mucosal resection of gastrointestinal tumors",
"     </li>",
"     <li>",
"      Percutaneous endoscopic gastrostomy tube placement",
"     </li>",
"     <li>",
"      Foreign body removal",
"     </li>",
"     <li>",
"      Pneumatic dilation or botulinum toxin injection for achalasia",
"     </li>",
"     <li>",
"      Placement of a wireless video capsule endoscope",
"     </li>",
"     <li>",
"      Placement of esophageal acid monitoring devices",
"     </li>",
"     <li>",
"      Endoscopic therapy for gastroesophageal reflux",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of upper endoscopy include complications due to sedation, bleeding, and perforation. (See",
"      <a class=\"local\" href=\"#H67011650\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/1\">",
"      Cotton PB, Hawes RH, Barkun A, et al. Excellence in endoscopy: toward practical metrics. Gastrointest Endosc 2006; 63:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/2\">",
"      Bjorkman DJ, Popp JW Jr. Measuring the quality of endoscopy. Gastrointest Endosc 2006; 63:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/3\">",
"      Appropriate use of gastrointestinal endoscopy. Gastrointest Endosc 2000; 52:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/4\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/5\">",
"      Lundeg&aring;rdh G, Adami HO, Helmick C, et al. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988; 319:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/6\">",
"      Tersmette AC, Goodman SN, Offerhaus GJ, et al. Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients. Am J Epidemiol 1991; 134:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/7\">",
"      MING SC, GOLDMAN H. GASTRIC POLYPS; A HISTOGENETIC CLASSIFICATION AND ITS RELATION TO CARCINOMA. Cancer 1965; 18:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/8\">",
"      Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/9\">",
"      Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/10\">",
"      Kokkola A, Sj&ouml;blom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/11\">",
"      Alexander JR, Andrews JM, Buchi KN, et al. High prevalence of adenomatous polyps of the duodenal papilla in familial adenomatous polyposis. Dig Dis Sci 1989; 34:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/12\">",
"      Aarnio M, Salovaara R, Aaltonen LA, et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997; 74:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/13\">",
"      Yatsuya H, Toyoshima H, Tamakoshi A, et al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case-control study. Br J Cancer 2004; 91:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/14\">",
"      Chen MJ, Wu DC, Ko YC, Chiou YY. Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in Taiwan. Am J Gastroenterol 2004; 99:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/15\">",
"      Boeing H. Epidemiological research in stomach cancer: progress over the last ten years. J Cancer Res Clin Oncol 1991; 117:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/16\">",
"      Yachimski P, Hur C. Upper endoscopy in patients with acute myocardial infarction and upper gastrointestinal bleeding: results of a decision analysis. Dig Dis Sci 2009; 54:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/17\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/18\">",
"      Faigel DO, Eisen GM, Baron TH, et al. Preparation of patients for GI endoscopy. Gastrointest Endosc 2003; 57:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/19\">",
"      American Society of Anesthesiologists Committee. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology 2011; 114:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/20\">",
"      Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002; 55:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/21\">",
"      Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy, Lichtenstein DR, Jagannath S, et al. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008; 68:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/22\">",
"      Sharma VK, Nguyen CC, Crowell MD, et al. A national study of cardiopulmonary unplanned events after GI endoscopy. Gastrointest Endosc 2007; 66:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/23\">",
"      Cohen LB, Delegge MH, Aisenberg J, et al. AGA Institute review of endoscopic sedation. Gastroenterology 2007; 133:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/24\">",
"      Standards of Practice Committee, Zuckerman MJ, Shen B, et al. Informed consent for GI endoscopy. Gastrointest Endosc 2007; 66:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/25\">",
"      Plumeri PA. Informed consent for gastrointestinal endoscopy in the '90s and beyond. Gastrointest Endosc 1994; 40:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/26\">",
"      Davis DE, Jones MP, Kubik CM. Topical pharyngeal anesthesia does not improve upper gastrointestinal endoscopy in conscious sedated patients. Am J Gastroenterol 1999; 94:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/27\">",
"      Faigel DO, Eisen GM, Baron TH, et al. Tissue sampling and analysis. Gastrointest Endosc 2003; 57:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/28\">",
"      Cohen J. The impact of tissue sampling on endoscopy efficiency. Gastrointest Endosc Clin N Am 2004; 14:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/29\">",
"      Eisen GM, Baron TH, Dominitz JA, et al. Complications of upper GI endoscopy. Gastrointest Endosc 2002; 55:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/30\">",
"      ASGE Standards of Practice Committee, Ben-Menachem T, Decker GA, et al. Adverse events of upper GI endoscopy. Gastrointest Endosc 2012; 76:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/31\">",
"      Silvis SE, Nebel O, Rogers G, et al. Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. JAMA 1976; 235:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/32\">",
"      Geraci G, Pisello F, Modica G, et al. [Complications of elective esophago-gastro-duodenoscopy (EGDS). Personal experience and literature review]. G Chir 2009; 30:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/33\">",
"      Wolfsen HC, Hemminger LL, Achem SR, et al. Complications of endoscopy of the upper gastrointestinal tract: a single-center experience. Mayo Clin Proc 2004; 79:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/34\">",
"      Quine MA, Bell GD, McCloy RF, et al. Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing, and sedation methods. Gut 1995; 36:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/35\">",
"      Arrowsmith JB, Gerstman BB, Fleischer DE, Benjamin SB. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. Gastrointest Endosc 1991; 37:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/36\">",
"      Darling R, Roughton F. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. Am J Physiol 1942; 137:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/37\">",
"      Henry LR, Pizzini M, Delarso B, Ridge JA. Methemoglobinemia: early intraoperative detection by clinical observation. Laryngoscope 2004; 114:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/9/12442/abstract/38\">",
"      Chirica M, Champault A, Dray X, et al. Esophageal perforations. J Visc Surg 2010; 147:e117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13928 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12442=[""].join("\n");
var outline_f12_9_12442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H67011687\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982066\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982073\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67012243\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67012372\">",
"      - Diagnostic examinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75116262\">",
"      - Caustic ingestions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67012411\">",
"      - Screening/surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67012364\">",
"      - Planned therapeutic intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67011540\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67012257\">",
"      Important considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982080\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67012131\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75116545\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67012139\">",
"      Management of anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75116514\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67012147\">",
"      SEDATION ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67011854\">",
"      INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67011548\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982087\">",
"      Intubation with the endoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982094\">",
"      Esophagus and esophagogastric junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982101\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982108\">",
"      Pyloric intubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982115\">",
"      Duodenum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67011595\">",
"      DIAGNOSTIC AND THERAPEUTIC MANEUVERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67011611\">",
"      Tissue sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982129\">",
"      PHOTODOCUMENTATION AND REPORTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1213982136\">",
"      TROUBLESHOOTING COMMON PROBLEMS IN UPPER ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67011650\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61432870\">",
"      Complications related to sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61432890\">",
"      Methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61433415\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61432898\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61433290\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67011687\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/13928\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13928|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/53/32595\" title=\"figure 1\">",
"      Gastric anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/37/41554\" title=\"figure 2\">",
"      Retroflexion of endoscope within the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 3\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13928|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/25/43410\" title=\"picture 1\">",
"      Endoscopic view of the hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/706\" title=\"picture 2\">",
"      Esophagogastric junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/7/10356\" title=\"picture 3\">",
"      Gastric folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/47/18162\" title=\"picture 4\">",
"      Retroflexed view esophagogastric junction and proximal stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/2/37922\" title=\"picture 5\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/30/33263\" title=\"picture 6\">",
"      Antrum and pylorus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/7/7284\" title=\"picture 7\">",
"      Endoscopic view of the duodenum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13928|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/15/30972\" title=\"table 1\">",
"      Indications for upper gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/54/35692\" title=\"table 2\">",
"      Risk factors and proposed screening recs for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/19/31037\" title=\"table 3\">",
"      ASGE guidelines Abx prophylxs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/60/14285\" title=\"table 4\">",
"      Abx prophylaxis regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=related_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/38/40551?source=related_link\">",
"      Caustic esophageal injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=related_link\">",
"      Complications of endoscopic esophageal stricture dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28310?source=related_link\">",
"      Complications of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=related_link\">",
"      Confocal laser endomicroscopy and endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=related_link\">",
"      Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6312?source=related_link\">",
"      Endoscope disinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25688?source=related_link\">",
"      Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28489?source=related_link\">",
"      Endoscopy in patients who have undergone bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=related_link\">",
"      Enteral stents for the palliation of malignant gastroduodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6809?source=related_link\">",
"      Expandable stents in the treatment of esophageal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=related_link\">",
"      Gastric outlet obstruction in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=related_link\">",
"      Gastric polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=related_link\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=related_link\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21353?source=related_link\">",
"      Ingested foreign bodies and food impactions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43317?source=related_link\">",
"      Mallory-Weiss syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18039?source=related_link\">",
"      Overview of the treatment of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12810?source=related_link\">",
"      Pneumatic dilation and botulinum toxin injection for achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34937?source=related_link\">",
"      Prevention and management of complications from percutaneous endoscopic gastrostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=related_link\">",
"      Radiofrequency ablation for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6983?source=related_link\">",
"      Screening and prevention of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/329?source=related_link\">",
"      Surgical management of esophageal perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=related_link\">",
"      Zenker's diverticulum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_9_12443="Differential diagnosis LIS";
var content_f12_9_12443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of locked-in syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Distinguishing clinical features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Anatomical lesion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Locked-in syndrome",
"      </td>",
"      <td>",
"       Quadriplegia with preserved vertical eye movements and consciousness",
"      </td>",
"      <td>",
"       Pontine base",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coma",
"      </td>",
"      <td>",
"       Unresponsive to stimuli, does not follow commands",
"      </td>",
"      <td>",
"       Bilateral cerebral or upper brain stem",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Akinetic mutism",
"      </td>",
"      <td>",
"       No spontaneity or motivation",
"      </td>",
"      <td>",
"       Bifrontal, deep gray matter, upper brain stem",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Catatonia",
"      </td>",
"      <td>",
"       Maintenance of body posture",
"      </td>",
"      <td>",
"       No CNS lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persistent vegetative state",
"      </td>",
"      <td>",
"       No higher cortical functions, does not follow commands, retained cardiovascular and respiratory functions",
"      </td>",
"      <td>",
"       Diffuse cerebral hemisphere",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12443=[""].join("\n");
var outline_f12_9_12443=null;
var title_f12_9_12444="Levels of dyspnea in ILD";
var content_f12_9_12444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Levels of dyspnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Level of dyspnea",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None (or same as peers) even after 30 min of vigorous",
"activity, such as running; ability to lift and carry 27 kg (60 lbs) for",
"a prolonged period of time",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After 5 flights of stairs or 10 min of vigorous",
"activity/prolonged use of heavy tools",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        After walking more than a mile (1609 m) on level ground",
"or up three flights of stairs; less than 10 min of vigorous activity,",
"such as running or tennis",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upon walking 0.25 to 1 mile (402 to 1604 m) on level",
"ground or up 2 flights of stairs; dyspnea with paper hanging",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upon walking 300 to 1,320 feet (91.4 to 402.3 m) on",
"level ground; bed-making*",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upon walking 150 to 300 feet (45.7 to 91.4 m) on level",
"ground or up 1 flight of stairs; scrubbing; truck driving;",
"assembly-line work&bull;",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upon walking 50 to 150 feet (15.2 to 45.7 m) on level",
"ground at approximately 3 mph; light janitorial work&bull;",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upon walking 20 to 50 feet (6.1 to 15.2 m) on level",
"ground; light steady work at one's own pace; seated operation of heavy",
"equipment&bull;",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With minor exertion, such as dressing, walking less",
"than 20 feet (6.1 meters), or prolonged talking&bull;",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        With minimal activity, such as eating, defecating,",
"writing, sitting up&bull;",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At rest&bull;",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Defined as moderately severe breathlessness.",
"     <br>",
"      &bull; Defined as severe breathlessness.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Watters, LC, King, TE, Schwarz, MI, et al, Am Rev Respir Dis 1986; 133:97.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12444=[""].join("\n");
var outline_f12_9_12444=null;
var title_f12_9_12445="Common misdiagnosis recluse spider bite";
var content_f12_9_12445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A list of medical conditions that have been or could be misdiagnosed as cutaneous loxoscelism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Group A",
"        <em>",
"         Streptococcus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        -",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"        &nbsp;(especially MRSA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Cutaneous anthrax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Gonococcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ricketsial disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Tularemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Deep fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Sporotrichosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Aspergillosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Cryptococcosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ecthyma gangrenosum (",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasitic (Leishmaniasis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral (herpes simplex, herpes zoster (shingles))",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Topical and exogenous causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns (chemical, thermal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic plant dermatitis (poison ivy, poison oak)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factitious injury (ie, self-induced)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure ulcers (ie, bed sores)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other arthropod bites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vascular occlusive or venous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiphospholipid-antibody syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Livedoid vasculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small-vessel occlusive arterial disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venous statis ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Necrotising vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytoclastic vaculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyarteritis nodosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Takayasu's arteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wegeners granulomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neoplastic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia cutis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma (eg, mycosis fungoides)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary skin neoplasms (basal cell carcinoma, malignant melanoma, squamous cell carcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphomatoid papulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcific uremic arteriolopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryoglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetic ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Langerhans'-cell histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus vegetans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyoderma gangrenosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic embolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vetter RS. Spiders of the genus Loxosceles (Araneae, Sicariidae): a review of biological, medical and psychological aspects regarding envenomations. Journal of Arachnology 2008; 36:150. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12445=[""].join("\n");
var outline_f12_9_12445=null;
var title_f12_9_12446="Failed airway algorithm";
var content_f12_9_12446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The failed airway algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 393px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In children under 8 years of age an uncuffed or cuffed endotracheal tube may be placed. In neonates, uncuffed endotracheal tubes should be placed.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12446=[""].join("\n");
var outline_f12_9_12446=null;
var title_f12_9_12447="Direct indirect opthalmoscopy";
var content_f12_9_12447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Direct versus indirect ophthalmoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    View of same fundus through (A) direct and (B) indirect ophthalmoscopes. Hemorrhage is not visible with the smaller field. Indirect ophthalmoscopy permits visualization of the optic nerve (asterisk), the fovea (arrow), the macula (within circle), and the periphery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kivlin, JD. Ophthalmic manifestations of shaken baby syndrome. Journal of Aggression, Maltreatment and Trauma 2001; 5:137. Copyright &copy;2001 The Haworth Press, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_9_12447=[""].join("\n");
var outline_f12_9_12447=null;
